Ali Zahedi-Amiri1,2, Glen L Sequiera3,4, Sanjiv Dhingra3,4, Kevin M Coombs5,6,7. 1. Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada. 2. Manitoba Centre for Proteomics and Systems Biology, Winnipeg, MB, Canada. 3. Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, MB, Canada. 4. Institute of Cardiovascular Sciences, Albrechtsen Research Centre, St. Boniface Hospital, Winnipeg, MB, Canada. 5. Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada. kevin.coombs@umanitoba.ca. 6. Manitoba Centre for Proteomics and Systems Biology, Winnipeg, MB, Canada. kevin.coombs@umanitoba.ca. 7. Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada. kevin.coombs@umanitoba.ca.
Abstract
Maternal influenza infection during pregnancy was reported multiple times as the possible cause of many defects and congenital anomalies. Apart from several cases of influenza-related miscarriage during various trimesters of pregnancy, some epidemiological data suggest a link between maternal influenza infection and genetic abnormalities in offspring. However, there are no reports yet describing how maternal influenza alters cellular pathways at early stages of development to result in congenital defects in the fetus. In the present study, using proteomic approaches, we utilized human-induced pluripotent stem cells (hiPSCs) for modeling intrablastocyst infection with influenza virus to not only investigate the vulnerability and responses of pluripotent stem cells to this virus but also to determine the possible impacts of influenza on pluripotency and signaling pathways controlling differentiation and embryogenesis. Our data indicated viral protein production in influenza A virus (IAV)-infected hiPSCs. However, viral replication was restricted in these cells, but cell viability and pluripotency were negatively affected. These events occurred simultaneously with an excessive level of IAV-induced autophagy as well as cytopathic effects. Quantitative SOMAscan screening also indicated that changes in the proteome of hiPSCs corresponded to abnormal differentiation in these cells. Taken together, our results showed that IAV-modulated reduction in hiPSC pluripotency is associated with significant activation of autophagy. Further investigations are required to explore the role of IAV-induced autophagy in leading pluripotent stem cells toward abnormal differentiation and impaired development in early stages of embryogenesis.
Maternal influenza infection during pregnancy was reported multiple times as the possible cause of many defects and congenital anomalies. Apart from several cases of influenza-related miscarriage during various trimesters of pregnancy, some epidemiological data suggest a link between maternal influenza infection and genetic abnormalities in offspring. However, there are no reports yet describing how maternal influenza alters cellular pathways at early stages of development to result in congenital defects in the fetus. In the present study, using proteomic approaches, we utilized human-induced pluripotent stem cells (hiPSCs) for modeling intrablastocyst infection with influenza virus to not only investigate the vulnerability and responses of pluripotent stem cells to this virus but also to determine the possible impacts of influenza on pluripotency and signaling pathways controlling differentiation and embryogenesis. Our data indicated viral protein production in influenza A virus (IAV)-infected hiPSCs. However, viral replication was restricted in these cells, but cell viability and pluripotency were negatively affected. These events occurred simultaneously with an excessive level of IAV-induced autophagy as well as cytopathic effects. Quantitative SOMAscan screening also indicated that changes in the proteome of hiPSCs corresponded to abnormal differentiation in these cells. Taken together, our results showed that IAV-modulated reduction in hiPSC pluripotency is associated with significant activation of autophagy. Further investigations are required to explore the role of IAV-induced autophagy in leading pluripotent stem cells toward abnormal differentiation and impaired development in early stages of embryogenesis.
Some influenza pandemics and seasonal epidemics have shown high rates of fatalities in pregnant women and the fetus, suggesting that pregnancy puts both mother and offspring at higher risk of developing flu complications[1]. In addition to influenza-induced miscarriages, maternal influenza infection was reported several times as possible cause of some developmental malformations, but the molecular mechanisms behind such teratogenic effects have remained elusive[2-6]. A few pathologic analyses have not only confirmed viremia and extrapulmonary spread of influenza in pregnant women but also its transmission to fetal tissues[7-10]. Influenza-modulated congenital defects are mostly believed to originate from early pregnancy when the unevolved and vulnerable placenta still develops. Although transplacental passage of this virus is debated, embryonic cells can be affected through feto-maternal viral interference in signaling pathways controlling embryogenesis. Influenza replicates in certain multipotent stem cells[11-13]. Nevertheless, Influenza A virus (IAV) has limited replication in mouse embryonic stem cells (mESCs), but reduces their viability even at low multiplicity of infection (MOI), indicating the vulnerability of the blastocyst’s inner cell mass (ICM) to IAV[14]. ESCs are pluripotent and present only transiently at the ICM before initiating embryogenesis. Pluripotency is an essential attribute of pluripotent stem cells (PSCs) and represents the stemness, differentiation capacity, and self-renewal ability of such cells. Interactions of influenza proteins with themselves and with host cell proteins elicit substantial changes in the proteome to expand viral replication, as noticed by several virus-induced impairments in host cellular machinery affecting apoptosis and autophagy, immune responses, and protein synthesis[15-21]. None of these influenza-mediated alterations have been studied under the pluripotent state on a proteomic scale. Cell death and survival signaling pathways in these, especially after viral infections, are also poorly understood[22]. Additionally, modifications in pluripotency, self-renewal, and differentiation, as the most critical characteristics of PSCs, have not yet been elucidated under infections with most viruses, including influenza. Human-induced pluripotent stem cells (hiPSCs), which are generated through reprograming somatic cells, show great promise as both ethical and functional alternatives to ESCs for in vitro modeling of intrablastocyst infections. In the present study, we investigated the effects of IAV on the pluripotency and the proteome of hiPSCs.
Results
Influenza A/PR/8/34 replicates restrictively in hiPSCs
Unlike MDCK and A549 epithelial cells, which are permissive to influenza, IAV growth was restricted in hiPSCs at MOIs of 0.1 and 1.0 (Fig. 1a, upper and middle panels). At 24 hpi, the maximum titer of 106 PFU/mL was attained at MOI of 5.0, which appeared to be upward and a little lower than the initial titer at 0 hpi (Fig. 1a, bottom panel). Despite no detectable protein expression at lower MOIs, viral matrix 1 protein (M1), nucleoprotein (NP), and nonstructural-1 protein (NS1) were produced in hiPSCs by 12 hpi at MOI of 5 (Fig. 1b). We further validated the expression of viral proteins and also noticed that an MOI of 5 was adequate to establish infection in nearly 80% of cells by 24 hpi (Fig. 1c). Although the assembly and maturation of infectious progeny viruses appeared to be limited, these data collectively indicate that influenza A/PR/8/34 enters the nucleus of hiPSC at higher MOIs and can initiate transcription and replication.
Fig. 1
Restricted replication of influenza A/PR/8/34 in hiPSCs.
a Comparison of PR8 virus growth kinetics between hiPSCs and IAV-permissive epithelial cell lines. hiPS, MDCK, and A549 cells were infected at various MOIs to track and compare viral yield. Supernatants were collected and titered in MDCK cells to measure viral growth by the standard plaque assay at different time points. b Immunoblot detection of IAV protein production in pluripotent stem cells. hiPSCs were infected with influenza A/PR/8/34 at MOI = 5 PFU/cell, and protein lysates were examined for production of viral NS1, NP, and M1 proteins at 12 and 24 h post infection by immunoblotting. c Validation of PR8 protein production in iPS cells by immunofluorescent microscopy. hiPS cells were infected for 24 h at MOI = 5 PFU/cell. After fixation, cells were probed with primary antibodies for viral proteins and imaged with a fluorescence microscope to detect NP (yellow), NS1 (red), and M1 (orange). Nuclei = blue (scale bar = 50 μm)
Restricted replication of influenza A/PR/8/34 in hiPSCs.
a Comparison of PR8 virus growth kinetics between hiPSCs and IAV-permissive epithelial cell lines. hiPS, MDCK, and A549 cells were infected at various MOIs to track and compare viral yield. Supernatants were collected and titered in MDCK cells to measure viral growth by the standard plaque assay at different time points. b Immunoblot detection of IAV protein production in pluripotent stem cells. hiPSCs were infected with influenza A/PR/8/34 at MOI = 5 PFU/cell, and protein lysates were examined for production of viral NS1, NP, and M1 proteins at 12 and 24 h post infection by immunoblotting. c Validation of PR8 protein production in iPS cells by immunofluorescent microscopy. hiPS cells were infected for 24 h at MOI = 5 PFU/cell. After fixation, cells were probed with primary antibodies for viral proteins and imaged with a fluorescence microscope to detect NP (yellow), NS1 (red), and M1 (orange). Nuclei = blue (scale bar = 50 μm)
Influenza causes cytopathology and activates autophagy in hiPSCs
By increasing the MOI, infected cells displayed more cytopathic effects (CPEs), such as shrinkage, rounding, detaching from the culture vessels, and notable reduction in the number and size of colonies, suggesting the induction of cell death (Fig. 2a, b). The viability of PR8-infected cells also was reduced (Fig. 2c). These observations confirm cytopathogenic entry of virus. Compared to A549 cells, IAV did not elevate the cleavage of caspases in hiPSCs by 24 hpi and showed unique cell-specific differences in the expression of apoptosis regulators like Bax, Bcl-2, and p53 (Fig. 2d, left and middle panels), highlighting constrained intrinsic apoptosis in hiPSCs after IAV infection. However, the induction of autophagy after influenza infection was demonstrated by detection of LC3β-II, Atg5, and p62 (Fig. 2d, right panel). Taken together, unlike limited intrinsic apoptosis, IAV activated autophagy in hiPSCs earlier than apoptosis executioners and to much higher levels.
Fig. 2
Influenza causes cytopathology and activates autophagy in hiPSCs.
a Visual examination of IAV-induced CPE in pluripotent stem cells. Mock and virus-infected cells at different MOIs were observed under an inverted microscope and photographed at 12 and 24 hpi (scale bar= 50 μm). b Impact of IAV on the size and numbers of hiPSC colonies. hiPSC colonies were infected with PR8 at three MOIs for 12 and 24 h, then fixed with 4% paraformaldehyde, and stained with crystal violet. Mock-infected colonies of hiPSCs showed deeper staining than infected colonies due to higher cell density per colony. c Quantification of Trypan blue exclusion test of cell viability at different MOIs and postinfection time points. In contrast to mock-infected cells, which remained more than 80% viable for a day, the viability of PR8-infected cells reduced significantly at 24 hpi for all MOIs compared to the mock 0 time and time-matched mock controls (P-value ≤ 0.01 = **, P-value ≤ 0.0001 = ****). d Effect of IAV infection on intrinsic apoptosis and autophagy activation. Following infection with PR8 virus at MOI of 5, cell lysates were extracted at 12 and 24 hpi, then fractionated by SDS-PAGE and assessed by western blotting. IAV proteins NP, M1, and NS1 were used as markers of infection. Left panel: compared to A549 cells, PR8 infection did not elevate the cleavage of caspases-7, -3, -9, the main executioners of the intrinsic apoptotic pathway, in hiPSCs by 24 hpi. Middle panel: in contrast to PR8-infected A549 cells which showed clear decrease in the expression of Bax (proapoptotic) at 24 hpi, hiPSCs expressed relatively unchanged levels of this protein within 24 h of infection with influenza, despite the slight reduction in infected cells. The abundance of Bcl-2 (antiapoptotic) was severely decreased one day after infection in both hiPS and A549 cells. Infecting these pluripotent stem cells with PR8 virus resulted in transient p53 accumulation only at 12 hpi without subsequent production at the later time points. Right panel: similar to A549s, IAV-induced autophagy was detected based on LC3β-I to II conversion, Atg5 accumulation, and p62 degradation
Influenza causes cytopathology and activates autophagy in hiPSCs.
a Visual examination of IAV-induced CPE in pluripotent stem cells. Mock and virus-infected cells at different MOIs were observed under an inverted microscope and photographed at 12 and 24 hpi (scale bar= 50 μm). b Impact of IAV on the size and numbers of hiPSC colonies. hiPSC colonies were infected with PR8 at three MOIs for 12 and 24 h, then fixed with 4% paraformaldehyde, and stained with crystal violet. Mock-infected colonies of hiPSCs showed deeper staining than infected colonies due to higher cell density per colony. c Quantification of Trypan blue exclusion test of cell viability at different MOIs and postinfection time points. In contrast to mock-infected cells, which remained more than 80% viable for a day, the viability of PR8-infected cells reduced significantly at 24 hpi for all MOIs compared to the mock 0 time and time-matched mock controls (P-value ≤ 0.01 = **, P-value ≤ 0.0001 = ****). d Effect of IAV infection on intrinsic apoptosis and autophagy activation. Following infection with PR8 virus at MOI of 5, cell lysates were extracted at 12 and 24 hpi, then fractionated by SDS-PAGE and assessed by western blotting. IAV proteins NP, M1, and NS1 were used as markers of infection. Left panel: compared to A549 cells, PR8 infection did not elevate the cleavage of caspases-7, -3, -9, the main executioners of the intrinsic apoptotic pathway, in hiPSCs by 24 hpi. Middle panel: in contrast to PR8-infected A549 cells which showed clear decrease in the expression of Bax (proapoptotic) at 24 hpi, hiPSCs expressed relatively unchanged levels of this protein within 24 h of infection with influenza, despite the slight reduction in infected cells. The abundance of Bcl-2 (antiapoptotic) was severely decreased one day after infection in both hiPS and A549 cells. Infecting these pluripotent stem cells with PR8 virus resulted in transient p53 accumulation only at 12 hpi without subsequent production at the later time points. Right panel: similar to A549s, IAV-induced autophagy was detected based on LC3β-I to II conversion, Atg5 accumulation, and p62 degradation
IAV infection diminishes pluripotency of hiPSCs
Although most infected cells showed pluripotency characteristics by 12 hpi (data not shown), an overall decrease of at least 20% was observed in the expression of pluripotency regulating proteins Nanog, Sox2, and Oct-4A after 24 h at MOI of 5.0 (Fig. 3d). The validation of these results showed similar or greater reduction in levels of pluripotency indicators at 24 hpi (Fig. 3e). IAVNS1 was almost equal between cells producing less Sox2 (Fig. 3b) or Oct-4A (Fig. 3c) and cells with a considerable level of these two proteins. However, apart from edges of infected colonies, NS1 appeared to be more abundant in cells expressing diminished levels of Nanog (Fig. 3a), showing that PR8 virus decreases the pluripotency for expanding its infectivity in hiPSCs.
Fig. 3
IAV is capable of reducing pluripotency.
The expression levels of pluripotency markers Nanog (green) (a), Sox2 (indigo) (b), and Oct-4A (yellow) (c) were measured by immunofluorescence microscopy at 24 hpi in the presence of viral NS1 protein as a marker for productive IAV infection. DNA counterstain is shown in blue (scale bar = 50 μm). d Quantification of florescence intensity for pluripotency-regulating proteins as well as IAV NS1. Signals of detected proteins were normalized to the level of nuclear staining hiPSCs. e Western blot analysis validates the influenza-mediated loss of pluripotency in hiPSCs. P-value > 0.05 = ns, P-value ≤ 0.05 = *, P-value ≤ 0.01 = **, P-value ≤ 0.001 = ***, P-value ≤ 0.0001 = ****
IAV is capable of reducing pluripotency.
The expression levels of pluripotency markers Nanog (green) (a), Sox2 (indigo) (b), and Oct-4A (yellow) (c) were measured by immunofluorescence microscopy at 24 hpi in the presence of viral NS1 protein as a marker for productive IAV infection. DNA counterstain is shown in blue (scale bar = 50 μm). d Quantification of florescence intensity for pluripotency-regulating proteins as well as IAVNS1. Signals of detected proteins were normalized to the level of nuclear staining hiPSCs. e Western blot analysis validates the influenza-mediated loss of pluripotency in hiPSCs. P-value > 0.05 = ns, P-value ≤ 0.05 = *, P-value ≤ 0.01 = **, P-value ≤ 0.001 = ***, P-value ≤ 0.0001 = ****
Inhibition of autophagy maintains pluripotency and limits viral growth
We found that more than 75% of hiPSCs remained viable after exposure to 50 nM Rapamycin, an autophagy promoter, for 24 h (Fig. 4a), while Bafilomycin, which inhibits autophagic activity, was more toxic for these cells, as their treatment with the same concentration resulted in a 50% drop in cell viability (Fig. 4b). Infection followed by treatment with 50 nM Rapamycin and 5 nM Bafilomycin decreased the viability to below 40% within 24 h, which is slightly less than the effect of infection alone in the absence of these drugs (Fig. 4c, d, left panels). Although the viral titer at 24 h after treatment with autophagy inducer did not pass its initial titer at time-point zero, viral yield was increased ~tenfold by Rapamycin (Fig. 4c, right panel) but, conversely, was decreased ~tenfold in Bafilomycin-treated cells (Fig. 4d, right panel), suggesting that selected concentrations affect IAV replication in hiPSCs. The conversion of LC3β-I to LC3β-II, and the degradation of P62, were significantly upregulated in Rapamycin-treated cells in both infected and noninfected conditions, compared to mock or nontreated controls, whereas autophagy indicators in Bafilomycin-treated cells, either infected or noninfected, were expressed almost similar to mock and nontreated control (Fig. 4e), which confirms the efficacy of selected concentrations in altering viral-induced autophagy in hiPSCs. Both infected and noninfected Rapamycin-treated cells showed 60% or more loss in the expression of pluripotency markers, which is more substantial than the effect of infection without Rapamycin (Figs. 3 and 4f). In Bafilomycin-treated cells, pluripotency proteins did not change significantly, but infection with PR8 virus caused slight reduction in their expressions, which were still between twofold and fourfold greater than signals for Rapamycin-treated cells, showing that Bafilomycin reduces the negative effect of influenza-mediated autophagy on pluripotency. Moreover, although our western blotting indicated that Bafilomycin-treated cells can express IAVNS1 protein almost equal to infected nontreated cells, we found that florescence signals for NS1 production were severely decreased and clustered under the influence of Bafilomycin, while the NS1 expression was highly increased by Rapamycin in different assays, compared to normal nontreated infected cells (Figs. 3 and 4e, f). Since both pharmacological promotion of autophagy by Rapamycin and influenza upregulate autophagic activity by inhibiting mechanistic target of rapamycin (mTOR), these results suggest a relationship between influenza-induced autophagy and loss of pluripotency.
Fig. 4
Effects of autophagy inhibition and induction on pluripotency and viral growth.
Cytotoxicity of Rapamycin (a) and Bafilomycin A1 (b) in hiPSCs and A549s. After treating cells with various concentrations of these drugs, cell viability was assessed by the WST-1 cell proliferation assay at 12 and 24 h. c Rapamycin increases the influenza titer (right panel), despite reducing cell viability in presence of PR8 virus (left panel). d Significant decline of viral titer in infected Bafilomycin-treated cells (right panel) is also associated with reduced cell viability (left panel). Assessment of viral titer was done by the plaque assay. e Expression levels of autophagy markers after exposure to autophagy inducer and inhibitor in infected and noninfected hiPSCs. After treating with drugs, cell lysates were assayed by immunoblotting for detection of LC3β-I to II conversion and p62 degradation. f Induction of autophagy negatively affects pluripotency, while the inhibition of autophagic activity maintains this characteristic of pluripotent stem cells. The expression of pluripotency proteins Nanog (green), Sox2 (violet), and Oct-4A (yellow) was determined at 24 hpi through immunocytochemistry in presence of viral NS1 protein as a marker for infection. DNA counterstain is shown in blue. P-value ≤ 0.05 = *, P-value ≤ 0.01 = **, P-value ≤ 0.001 = ***, P-value ≤ 0.0001 = ****. Scale bar = 20 μm
Effects of autophagy inhibition and induction on pluripotency and viral growth.
Cytotoxicity of Rapamycin (a) and Bafilomycin A1 (b) in hiPSCs and A549s. After treating cells with various concentrations of these drugs, cell viability was assessed by the WST-1 cell proliferation assay at 12 and 24 h. c Rapamycin increases the influenza titer (right panel), despite reducing cell viability in presence of PR8 virus (left panel). d Significant decline of viral titer in infected Bafilomycin-treated cells (right panel) is also associated with reduced cell viability (left panel). Assessment of viral titer was done by the plaque assay. e Expression levels of autophagy markers after exposure to autophagy inducer and inhibitor in infected and noninfected hiPSCs. After treating with drugs, cell lysates were assayed by immunoblotting for detection of LC3β-I to II conversion and p62 degradation. f Induction of autophagy negatively affects pluripotency, while the inhibition of autophagic activity maintains this characteristic of pluripotent stem cells. The expression of pluripotency proteinsNanog (green), Sox2 (violet), and Oct-4A (yellow) was determined at 24 hpi through immunocytochemistry in presence of viral NS1 protein as a marker for infection. DNA counterstain is shown in blue. P-value ≤ 0.05 = *, P-value ≤ 0.01 = **, P-value ≤ 0.001 = ***, P-value ≤ 0.0001 = ****. Scale bar = 20 μm
PR8 infection alters the hiPSC proteome
Our SOMAscan® screening detected more significantly differentially expressed proteins at 24 hpi than at 12 hpi (Fig. 5a, Table 1). About 6% of the measured proteome underwent significant modifications by IAV (Fig. 5b). Most of upregulated and downregulated proteins at 12 hpi followed their significant altered pattern of expression to 24 hpi (Fig. 5c). Validating the differential regulations of some proteins revealed similar expression patterns (Fig. 5d). Most of the affected proteins at 12 hpi were mapped in extracellular (secretory) (39.3%) and plasma membrane (30.3%) regions. These two areas collectively contained 54.7% of influenza-modulated proteins at 24 hpi (Fig. 5e).
Fig. 5
SOMAscan proteomic analysis of IAV-infected hiPSCs.
a Volcano plots showing the expression fold changes and the significance of differentially expressed proteins at 12 and 24 hpi (P-value < 0.05). b The heatmap of the whole proteome (upper image) and the comparison (lower image) heatmap of differentially expressed proteins. c Venn diagram of the overlapping proteins between two time-points. Diagrams of significantly regulated proteins were plotted using InteractiVenn free online software. d Western blot confirmation of selected differentially regulated proteins from SOMAscan results. Western blot results are represented from multiple different gels. Various loading control band intensities were used from different gels to perform densitometry normalization and analysis. For validation, proteins were selected based on fold changes, availability of antibodies, and involvement in pluripotency and differentiation. These proteins include serotransferrin (TF), osteonectin (SPARC), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), signal transducer and activator of transcription 3 (STAT3), and proteasome subunit alpha type-2 (PSMA2). Influenza NS1 also was probed to confirm successful infection. e The subcellular localizations of regulated proteins at 12 and 24 hpi. Graphical representation of cellular compartments was illustrated using pathway designer plugin in the IPA tool. Up- and downregulated proteins are highlighted in red and green, respectively
Mitogen-activated protein kinase-activated protein kinase 3
−1.41
2.15E−01
−1.68
1.84E−02
STAT3
Signal transducer and activator of transcription 3
−1.40
1.73E−01
−1.70
2.30E−02
EIF4A3
Eukaryotic translation initiation factor 4A3
−1.39
2.23E−01
−1.74
9.16E−03
ERBB3
erb-b2 receptor tyrosine kinase 3
−1.43
1.39E−01
−1.77
1.49E−02
HSD17B10
Hydroxysteroid 17-beta dehydrogenase 10
−1.11
6.21E−01
−1.82
2.06E−02
INSR
Insulin receptor
−1.38
2.73E−01
−1.93
1.28E−02
CSK
C-terminal Src kinase
−1.58
2.76E−01
−2.06
9.52E−03
CKM
Creatine kinase, M-type
−1.48
3.88E−01
−2.32
2.85E−02
ROR1
Receptor tyrosine kinase like orphan receptor 1
−1.35
2.60E−01
−2.39
2.18E−03
PKM2
Pyruvate kinase M1/2
−1.48
5.20E−01
−3.06
4.48E−02
SOMAscan proteomic analysis of IAV-infected hiPSCs.
a Volcano plots showing the expression fold changes and the significance of differentially expressed proteins at 12 and 24 hpi (P-value < 0.05). b The heatmap of the whole proteome (upper image) and the comparison (lower image) heatmap of differentially expressed proteins. c Venn diagram of the overlapping proteins between two time-points. Diagrams of significantly regulated proteins were plotted using InteractiVenn free online software. d Western blot confirmation of selected differentially regulated proteins from SOMAscan results. Western blot results are represented from multiple different gels. Various loading control band intensities were used from different gels to perform densitometry normalization and analysis. For validation, proteins were selected based on fold changes, availability of antibodies, and involvement in pluripotency and differentiation. These proteins include serotransferrin (TF), osteonectin (SPARC), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), signal transducer and activator of transcription 3 (STAT3), and proteasome subunit alpha type-2 (PSMA2). InfluenzaNS1 also was probed to confirm successful infection. e The subcellular localizations of regulated proteins at 12 and 24 hpi. Graphical representation of cellular compartments was illustrated using pathway designer plugin in the IPA tool. Up- and downregulated proteins are highlighted in red and green, respectivelyhiPSC proteins affected by PR8 infection
Interconnecting networks of proteins were created using Ingenuity Pathways Analysis (IPA) software to determine interactions among dysregulated proteins in influenza-infected hiPSCs (Supplementary Fig. 1). Most of the significantly regulated proteins in the embryonic development network were downregulated by IAV (Fig. 6a). IPA also predicted potential inhibition or activation of other member molecules in this network that were not regulated or not found in our dataset (Fig. 6b). Experimental data and bioinformatic prediction connected this network to bio-functions related to stem cells and embryogenesis (Fig. 6c). These influenza-induced dysregulations in protein–protein interaction networks may negatively affect differentiation and embryogenesis.
Fig. 6
Influenza affects proteins regulating embryonic development network.
a Changes in embryonic development network across two time-points. b IPA prediction on the expression patterns of molecules that belong to the embryonic development network but not found to be either differentially regulated or identified in our datasets. c Selection of some bio-functions that were predicted to be inhibited based on this network. These functions are mostly related to early differentiation phase of embryonic stem cells and embryogenesis. The datasets containing protein IDs, fold changes, and P-values were imported into the IPA software, and interacting networks were assembled for differentially expressed proteins. Up- and downregulated proteins are indicated in red and green, respectively; gray proteins denote that they were identified in this study but not affected; colorless proteins interact with various proteins in the network but were not recognized by our SOMAscan screening. IPA “Grow tool” and bioinformatic predictions were used to connect bio-functions to the network
Influenza affects proteins regulating embryonic development network.
a Changes in embryonic development network across two time-points. b IPA prediction on the expression patterns of molecules that belong to the embryonic development network but not found to be either differentially regulated or identified in our datasets. c Selection of some bio-functions that were predicted to be inhibited based on this network. These functions are mostly related to early differentiation phase of embryonic stem cells and embryogenesis. The datasets containing protein IDs, fold changes, and P-values were imported into the IPA software, and interacting networks were assembled for differentially expressed proteins. Up- and downregulated proteins are indicated in red and green, respectively; gray proteins denote that they were identified in this study but not affected; colorless proteins interact with various proteins in the network but were not recognized by our SOMAscan screening. IPA “Grow tool” and bioinformatic predictions were used to connect bio-functions to the network
PR8 virus dysregulates pathways and bio-functions regulating cell differentiation
IPA identified IAV-modulated pathways in hiPSCs (Fig. 7a, b), some of which are involved in differentiation and pluripotency. The effects of IAV on the member molecules of these pathways are shown in Supplementary Fig. 2. We also generated networks of molecules altered by the virus that individually or collectively mediate modifications in affected pathways (Fig. 7c, d). IPA also predicted decreases in differentiation, embryogenesis, and cell viability, and increase in cell death by 12 hpi (Fig. 8a), indicating that IAV initially causes cell death and suppressed differentiation. Nevertheless, activation of cellular development at 24 hpi (Fig. 8b) suggests the possibility of differentiation.
Fig. 7
Top-affected canonical pathways in hiPSCs after PR8 infection.
Protein IDs together with their P-values and levels of regulation were uploaded into IPA tool. In the canonical pathway section, P-values of pathways were automatically calculated by the software and top significantly affected pathways were graphed for 12 hpi (a) and 24 hpi (b). Because the affected member molecules from these targeted pathways were fewer than the total numbers of molecules present in those pathways based on SOMAscan screening, IPA software did not predict significant inhibition or activation patterns for the vast majority of influenza-modulated signaling pathways. c, d Network of common molecules mediating influenza-induced alterations into top-affected canonical pathways at 12 and 24 hpi. Up- and downregulated proteins are shown in red and green, respectively
Fig. 8
IPA prediction of top affected bio-functions by differentially expressed proteins at 12 hpi (a) and 24 hpi (b).
In the bio-function section of IPA, activation and inhibition z-scores were automatically calculated by the software and top significantly affected functions were merged and displayed as networks with auto layout. Z-scores values of ≥1.96σ and ≤−1.96σ were specified as the criteria for activation and inhibition patterns
Top-affected canonical pathways in hiPSCs after PR8 infection.
Protein IDs together with their P-values and levels of regulation were uploaded into IPA tool. In the canonical pathway section, P-values of pathways were automatically calculated by the software and top significantly affected pathways were graphed for 12 hpi (a) and 24 hpi (b). Because the affected member molecules from these targeted pathways were fewer than the total numbers of molecules present in those pathways based on SOMAscan screening, IPA software did not predict significant inhibition or activation patterns for the vast majority of influenza-modulated signaling pathways. c, d Network of common molecules mediating influenza-induced alterations into top-affected canonical pathways at 12 and 24 hpi. Up- and downregulated proteins are shown in red and green, respectively
IPA prediction of top affected bio-functions by differentially expressed proteins at 12 hpi (a) and 24 hpi (b).
In the bio-function section of IPA, activation and inhibition z-scores were automatically calculated by the software and top significantly affected functions were merged and displayed as networks with auto layout. Z-scores values of ≥1.96σ and ≤−1.96σ were specified as the criteria for activation and inhibition patterns
Discussion
Many questions concerning the effect of viruses on the unique characteristics of PSCs, like pluripotency, differentiation, and cell death signals, have remained unanswered. Here, we showed that IAV propagates restrictedly in hiPSCs. Wash et al. observed similar limited IAV replication in mESCs[14]. In our study, higher MOI did not promote PR8 replication but allowed synthesis of viral proteins, including NS1, which alone confirms the transport of viral ribonucleoproteins (vRNPs) into the nucleus, and initiation of transcription and translation. Compared to another (−)ssRNA viruses such as measles, which replicates more in iPSCs[23], the assembly of progeny IAV viruses was disrupted in our experiments, even though viral proteins synthesized at higher MOI confirm the cell's transcription machinery is hijacked by IAV. It has been speculated that underdeveloped glycosylation in PSCs hinders viral haemagglutinin (HA) and neuraminidase (NA) maturation[14,24-27], thereby resulting in not only reduced binding to cell receptors and less fusion with endosomal membrane but also decreased budding of new virions. The rapid proliferation of PSCs might also have negatively influenced the initial MOI and ultimately the ability of IAV to release measurable progeny, as already reported in ESCs infected with other (−)ssRNA viruses like La Crosse virus (LACV) and Sendai virus[28]. Growth conditions of these cells can also make barriers in simulating a normal in vivo infection. For instance, since iPSCs are grown in colonies on Matrigel-coated surfaces and cannot make confluent monolayers, viruses, as charged particles, might be limited in movement toward colonies because of being partially trapped in Matrigel[23,29], suggesting efficacy of higher MOIs for sufficient attachment and entry.We observed that PR8-infected hiPSCs develop CPE. This phenomenon was consistent with low cell viability. Similar CPE and loss in cell viability were reported in IAV-infected mESCs[14]. Some (−)ssRNA viruses like Measles with efficient replication and LACV with low viral yield, can also develop diverse types of CPE in hiPSCs and mESCs, respectively[23,28,30]. Our observation may suggest that if IAV infection occurs at the blastocyst stage, embryogenesis could be disrupted in cases of transplacental passage as the ICM is directly affected. We also attempted to discover the type of cell death that was elicited by IAV in hiPSCs with primary emphasis on apoptosis, the most common type of programmed cell death that can be induced by IAV through intrinsic and extrinsic mechanisms[31,32]. We showed that PR8 virus does not contribute to intrinsic apoptosis in hiPSCs, as noted by inactivation of caspases, but induces this type of cell death in lung epithelial A549 cells based on differential expression of caspases and apoptosis regulators. Such a cell-specific difference confirms unique expression profiles of intrinsic apoptosis executioners and regulators in hiPSCs. In somatic cells, apoptosis can be temporarily blocked by IAVNS1 protein at preliminary stages of infection via PI3k-Akt signaling pathway for expanding viral replication[33-35]. This early inhibition of apoptosis then is accompanied by apoptotic or necrotic pathways at subsequent phases of infection to promote cell death in infected cells and viral budding[36]. In our study, intrinsic apoptotic response might become activated later (e.g., after 24 hpi), which we did not investigate here because of decreased cell viability. IAV-induced cell death in hiPSCs might also have occurred via caspase-independent mechanisms (e.g., by extrinsic apoptosis or alternative cell death pathways).The acidification of endosome-lysosome system is needed for proper function of lysosomal enzyme and fusion of autophagosome with lysosome to complete autophagy, the pathway controlling degradation of dysfunctional organelles and recycling of cellular components[37]. This also provides an optimal condition for uncoating IAV particles and release of RNPs[36,38,39]. Interestingly, IAV induces autophagy in a variety of mammalian cells by inhibiting mTOR[17,40,41]. Considering the possibility of cell death with autophagy[42], we detected activation of autophagy in both influenza-infected A549s and hiPSCs. To our knowledge, this is the first evidence of virus-induced autophagy in PSCs, despite the lack of proof to directly link this activated mechanism to demonstrated cell death. After fertilization, autophagy levels were immediately upregulated in murine oocytes[43]. Subsequently, autophagy is inhibited between the one- and two-cell stage but can be increased again at the four-cell stage[44]. However, this mechanism is not clearly understood under pluripotent state and seemed to be stable and dispensable in ESCs. Consequences of suppressed autophagy in PSCs can be evolved during embryogenesis or later in differentiated cells and include neuronal inclusions, reduced adipose mass, unwanted accumulation of damaged organelles, and defective embryoid body formation in culture with insufficientATP production[45,46]. In contrast, implications of excessive abnormally induced autophagy may manifest subtlety in undifferentiated PSCs or in derived tissues and yet remain to be determined. The ubiquitin-proteasome system (UPS) may compensate for intrinsically low levels of autophagy in pluripotent state, due to high proteasome activity in these undifferentiated cells. Conversely, polyubiquitinated proteins are highly expressed in differentiated cells, and proteasome activity is progressively inhibited during differentiation process[47]. Furthermore, higher levels of autophagy were naturally observed during the differentiation of ESCs, probably through degrading protein complexes regulating pluripotency[48]. Many viruses develop mechanisms to evade, subvert, or exploit cellular processes for their benefit. We speculate that IAV induces autophagy in hiPSCs differently from its normal upregulation upon certain conditions. Such an altered viral-triggered mechanism under pluripotency state suggests the possibility of abnormal differentiation, as elevated levels of autophagy are usually seen in differentiating PSCs. It is thus necessary to evaluate the pluripotency and capacities of these cells for normal differentiation into germ layers after IAV infection to decipher the role of influenza-induced autophagy in abnormal embryonic specification. Hypothetically, with regards to demonstrated cell death, the virus may simultaneously put iPSCs under differentiation and promote autophagy, or may keep them in an undifferentiated state while increasing autophagic activity. It is also possible that the expected differentiation is not directly modulated by the virus itself and could be the outcome of virus-induced excessive autophagy. In all cases, cell death could be executed via different pathways and whether autophagy is actually playing a role in the cellular demise of iPSCs remains unclear[42].The effects of viral replication or entry on pluripotency have not yet been described for most viruses. Moreover, specifying the level of pluripotency indicates the possibility of differentiation in virus-infected iPSCs. We found influenza-infected hiPSCs to exhibit a remarkable decrease in the expression of pluripotency regulating proteins Nanog, Sox2, and Oct-4A. This is the first evidence so far that proves PR8 infection negatively affects the pluripotency of hiPSCs. Measles, as the only other (−)ssRNA virus tested for its effect on pluripotency, was incapable of altering this intrinsic feature of PSCs, but blocks their directed differentiation to germ layers due to extensive CPEs[23]. Significant levels of cell death that happened by 24 hpi and necessity of using higher MOI did not allow us to test the capability of PR8-infected cells for further differentiation into germ layers. Nevertheless, reduced pluripotency noted in the current study together with our findings regarding IAV-induced autophagy highlight a link between excessive autophagy and loss of pluripotency. Some studies suggest that mTOR acts as the regulator of pluripotency and self-renewal in hESCs, in addition to its central role in the regulation of the autophagy pathway and triggering several downstream pathways including PI3-kinase/Akt and AMP-activated protein kinase[44,49,50]. Zhou and coworkers reported a set of outcomes in hESCs after inhibition or depletion of mTOR, including considerable reduction in expression of Oct4 and Sox2, elevated mesoderm and endoderm differentiation, and limited proliferation[51]. At 24 hpi, we obtained similar results; decreased expression of Oct4 and Sox2 after influenza-induced autophagy. Additionally, our SOMAscan proteomic screening revealed evidence of potentially abnormal differentiation based on dysregulated proteins at the same postinfection time point. In A549 cells, mTOR inhibition with Rapamycin was reported to upregulate autophagy and production of viral NP and NS1 proteins, but did not increase viral yield[36]. We also pharmacologically inhibited mTOR in hiPSCs using Rapamycin and noticed significant loss of pluripotency, but higher levels of viral growth, viral protein production, and autophagic activity. In our study, PR8-infected hiPSCs showed not only evidence of viral protein production but also restricted viral replication and caspase-independent or nonapoptotic cell death under excessive autophagic activity. Irrespective of our previous assumptions about the type of cell death and possible reasons for limited viral replication, it has also been hypothesized that mTOR suppression stimulates upstream receptor tyrosine kinase signaling, subsequently activating the Akt/PKB pathway, which may inhibit apoptosis. According to a transcriptomic analysis, mTOR is upregulated during differentiation and afterward compared to its expression under the pluripotent state[52]. We did not directly evaluate the expression of mTOR in IAV-infected hiPSCs. However, our SOMAscan proteomic screen showed that some mTOR-signaling molecules like FGFR1 and INSR1, that are expected to be upregulated upon pathway activation, were downregulated by 24 hpi, suggesting potential IAV-triggered inhibition of this pathway. Hence, our results, and those of others, suggest that PR8 virus promotes autophagy in these PSCs, possibly by downregulating mTOR, which decreases pluripotency, ultimately inducing abnormal differentiation. Further investigations are required to explain the initiation of influenza-induced autophagy in PSCs and its possible effect on differentiation.Our proteomic analyses showed that PR8 virus altered the proteome of hiPSCs. This observation is consistent with what has been previously reported about the limited responses of these cells to most viruses[53]. Likewise, mESCs had also indicated minor dysregulations at the transcriptomic level after 6 h of infection with influenza[14]. Such limited host responses to influenza infection might be because of inhibited viral replication in these pluripotent cell populations. At 12 hpi, although a few proteins like Interleukin-29 (IL-29/IFNL1) and Interferon-stimulated gene 15 (ISG15), that are involved in type 3 and 1 interferon responses, were upregulated less than twofold, an apparent deficiency was noticed in the expression of proteins related to innate immune responses against viruses. Inactivated immune responses were already seen in PSCs after different viral or bacterial infections and are mainly due to underdeveloped innate immunity and mutual inhibition between the IFN system and pluripotent state in these cells[53-55]. Highly conserved regulation of transcription in ESCs can be considered another condition that may downregulate interferon-stimulated genes for maintaining pluripotency[14,56]. Bioinformatic analyses of differentially regulated proteins at 12 hpi also highlighted significant negative impacts on activation of some canonical pathways controlling immune responses, including leukocyte extravasation signaling, IL-2 signaling, and IL-6 signaling. It is possible that the 1.5-fold upregulation of ISG15 at this time point can be partially explained by the intrinsic immature immunity of PSCs to IAV, as it has been shown that this protein can ISGylate IAVNS1 protein which leads to the inefficiency of NS1 and limited viral replication, the same situation we observed experimentally. IPA software also predicted some potentially affected bio-functions, and these data collectively support the induction of cell death by either necrosis or apoptosis, reduction of cell viability, and inhibition of differentiation in ESCs. We found these bioinformatic predictions reliable and consistent with what we have already acquired on induction of cell death and stable pluripotency at 12 hpi. Even though we did not show the normal expression of pluripotency markers by 12 hpi through other assays, our proteomic screening determined the upregulation of Nanog, thus confirming the pluripotency of PR8-infected hiPSCs and repressed differentiation at the mentioned time point. In contrast, at 24 hpi, IPA detected unexpected dysregulations among some top-affected canonical pathways that are involved in processing differentiation and embryogenesis. More studies should be carried out to test whether IAV-induced changes could influence the normal differentiation of PSCs into germ layers.In conclusion, our results indicated IAV causes cytopathology in hiPSCs and can reduce their viability and pluripotency. It was also noticed that such an IAV-triggered decline in pluripotency is associated with an excessive level of autophagy. Moreover, our proteomic screening suggests dysregulations in several cellular pathways and bio-functions regulating differentiation. Further studies are needed to discover the molecular mechanisms involved in initiation of influenza-induced autophagy in PSCs and their possible effects on the signaling pathways controlling embryogenesis.
Materials and methods
Cells and viruses
hiPS cells were generated from human peripheral blood mononuclear cells (PBMCs) using the Sendai virus Kit (Life Technologies), as described previously[57]. All protocols were approved by the Research Ethics Board (REB) of the University of Manitoba. Humaninfluenza virus strain A/PR/8/34 (H1N1; PR8), an attenuated mouse-adapted strain, was amplified in MDCK cells by infecting at MOI of 0.01 for 48 h and concentrated at 64,000 × g for 2 h at 4 °C. The virus was then titered by the plaque assay on MDCK cells.
Infection and plaque assay
After washing semiconfluent hiPSC colonies 2× with 1× phosphate buffered saline (PBS; 137 mM NaCl, 0.3 mM KCl, 0.8 mM Na2HPO4, 0.1 mM KH2PO4), cells were infected with PR8 virus diluted in E8 medium to achieve different MOIs, including 0.1, 1, and 5 plaque forming units (PFU)/cell. To compare IAV growth kinetics in hiPSCs with other influenza-permissive cell lines, A549 and MDCK cells also were infected at the same MOIs by diluting the PR8 virus in gel saline (137 mM NaCl, 0.2 mM CaCl2, 0.8 mM MgCl2, 19 mM HBO3, 0.1 mM Na2B4O7, 0.3% (w/v) gelatin). An equivalent number of cells were mock-infected using either only E8 medium for PSCs or gel saline for other cells. At 12 and 24 hpi, infected and mock-infected hiPS and A549 cells were harvested for immunoblotting. To quantify the virus yield by the plaque assay, supernatants were collected from all three cell types at assigned time points and serially diluted 1:10 in gel saline. Diluted supernatants then were added to subconfluent monolayers of MDCK cells plated in six-well dishes. Following an hour adsorption, cells were overlaid with 0.8% Avicel in FBS-free 1× DMEM media containing 2 mM l-glutamine, 2 mM sodium pyruvate, and 1× MEM nonessential amino acids, and supplemented with 2.5 μg/mL trypsin, 1× gentamicin and 1× amphotericin B. After 72 h incubation at 35 °C to permit plaque formation, cells were fixed with 2% formaldehyde for 30 min and then stained with crystal violet for 1 h. Viral titer was calculated as PFU/mL by counting plaques 4 h after washing stained cell monolayers[58].
Immunoblotting
At time points 12 and 24 hpi, mock- and influenza-infected hiPS and A549 cells were scraped into cold PBS, then pelleted at 500 × g for 6 min, and lysed for 15 min in mammalian protein extraction reagent (M-PERTM, Thermo Scientific) supplemented with HALTTM protease inhibitor (Thermo Scientific). After clearing cell lysates by centrifugation at 14,000 × g for 15 min, supernatant protein contents were collected, and the BCA Protein Assay Kit (Pierce, Thermo Scientific) was applied to measure protein concentrations. Equal amounts of proteins were loaded per lane into SDS-polyacrylamide gels (SDS-PAGE), fractionated, and transferred to Immobilon-P polyvinylidene difluoride membranes (Millipore). Membranes were blocked with 5% skim milk in Tris-Buffered Saline buffer containing 0.1% Tween 20 for 2 h, and then incubated overnight with the desired primary antibodies at 4 °C. Influenza primary anti-NP, -M1, and -NS1 antibodies were developed in-house[59]. Primary antibodies for caspases-3, -7, -9, P53, Nanog, Sox2, Oct-4A, Bax, Bcl-2, PSMA2, STAT3, SPARC, GAPDH, p62, and β-actin were purchased from Cell Signaling Technology. The LC3β and Atg5 antibodies were obtained from InvitrogenTM and anti-Transferrin antibody was purchased from Abcam. Following overnight incubation with primary antibodies, membranes were probed with either rabbit or mouse HRP-conjugated secondary antibody (Cell Signaling) for 1 h at room temperature, and the bands were visualized through enhanced chemiluminescence detection machine (Amersham-Pharmacia Biotech). ImageJ software was used to quantify virus-to-mock ratios from the intensity of visualized bands. Blot quality was optimized for contrast and brightness using image settings plugin of Microsoft Word.
Analysis of cellular morphology
To examine PR8-induced CPE development, infected and mock-infected hiPSCs were assessed by inverted microscopy (Nikon TE-2000) at intended MOIs and photographed using a Canon A700 camera. The analysis of stem cell colony mass and size was done through crystal violet staining in a 12-well plate. After washing three times with PBS, hiPSCs were fixed with 4% paraformaldehyde for 15 min and then stained with 0.5% crystal violet solution in 4% paraformaldehyde for 10 min. The stained plate was washed twice with water, and infected colonies were evaluated and compared to mock-infected wells on the next day.
Assessment of cell viability
The trypan blue exclusion assay was used to determine cell viability. Briefly, PR8-infected or mock-infected hiPSCs were harvested at various postinfection time points by brief trypsinization to break up the colonies. Single cells derived from disaggregated colonies then were washed, stained with trypan blue solution and placed on a hemocytometer for counting. The percentage of viable cells was calculated based on the number of dead (blue) cells divided by the total number of cells counted, multiplied by 100. The cytotoxicity of autophagy drugs (Rapamycin and Bafilomycin) was determined by the WST-1 cell proliferation assay (Roche, Germany) according to the manufacturer's instructions. In brief, hiPSCs or A549s grown in 96‐well plates were treated with WST‐1 reagent for 90 min at 37 °C. Colorimetric changes were measured, and cell viability then was calculated compared with controls.
Indirect IF microscopy
For IF staining, iPSCs were grown to 60% confluence on chamber slides and then infected or mock-infected with the PR8 virus at MOI = 5. After fixing with 4% paraformaldehyde for 15 min at 12 and 24 hpi, cells were permeabilized with 0.1% Triton X-100 in PBS for 5 min and blocked with 3% BSA blocking solution for 90 min. Afterward, cells were incubated overnight 4 °C with primary anti-Nanog, -Sox2, -Oct-4A (all three from Cell Signaling), -NS1, -NP, and -M1 (all three made in-house) antibodies diluted in 1% BSA and PBS. After overnight incubation, cells were washed 5× with PBT buffer (PBS with 0.2% Tween-20) and treated for 1 h with Alexa Fluor™ 488 and 546 (Invitrogen) secondary antibodies. Slides were then mounted using DAPI-Prolong® Gold Antifade for nuclear staining, sealed and preserved at 4 °C for imaging on the following day. Fluorescent images were acquired at 20× and 40× objective by Zeiss Axio Observer Z1 inverted microscope and further optimized with AxioVision 4.8.2 software. ImageJ software was used to quantify the levels of florescence signal intensities.
Inhibition and activation of autophagy
To establish a relationship between autophagy induction and loss of pluripotency, autophagic activity was blocked using autophagy inhibitorBafilomycin A1 (Cayman Chemical), which inhibits autophagy through both hindering vacuolar acidification required for autophagosome maturation and mTOR activation[60,61]. Rapamycin (Sigma-Aldrich), an mTOR inhibitor and autophagy inducer[62], was utilized for elevating the level of autophagy. Both drugs were used in four different concentrations of 4000, 500, 50, and 5 nM for cytotoxicity analyses. Based on cell viability results, lower concentrations were selected for evaluating viral growth, autophagy, and pluripotency. In influenza-infected conditions, cells were first adsorbed with the virus at MOI of 5.0 for 1 h and then treated with selected concentration of Bafilomycin (5 nM) or Rapamycin (50 nM) mixed in cell-specific culture medium.
SOMAscan screening
After measuring protein concentrations in three biological replicates by the BCA assay, cell lysates were adjusted to 200 μg/ml and sent for proteomic screening using an in-house SOMAscan assay platform (version 1.3), a novel multiplexed system that uses modified nucleotides with high affinity known as SOMAmers (Slow Off-rate Modified Aptamers) to evaluate changes in the expression of intracellular proteins related to various biological processes[63]. In total, the expressions of 1307 proteins were determined from lysates isolated at 12 and 24 hpi from mock-infected and infected hiPSCs at MOI of 5. Raw specific protein abundance values were obtained as relative fluorescence units (RFU). To sort out modified proteins, we calculated z-scores separately for each biological replicate to normalize all screened proteins at a 95% confidence level cutoff. Z-scores values of ≥1.96σ and ≤−1.96σ were specified as the criteria for up- and downregulation patterns.
Statistical and bioinformatic analysis
Data were collected in triplicate from all experiments. For growth curves, cell viability, and band intensity analyses, statistical differences were assessed by one-way or two-way ANOVA, graphed using Graph Pad Prism 6.0, and results were reported as means ± SDE. P-values < 0.05 were considered statistically significant. To analyze SOMAscan results, RFU raw expression values were imported into Microsoft Excel and converted to Log2 for calculating fold changes. P-values were determined using the two-tailed Student's t-test. To compare various biological replicates, z-scores were calculated from protein ratios within each replicate, as previously described[58,63]. Briefly, all fold changes not deemed to be significant by t-test were examined by z-score, expressing each value as its number of standard deviations away from the population mean. Protein IDs from the whole examined proteome were uploaded to and analyzed by IPA software. Panther databases were utilized to classify all significantly expressed proteins in gene ontology categories. Venn diagrams and heatmap were plotted using InteractiVenn and MORPHEUS (developed by Broad Institute, Cambridge, MA, USA) free online software, respectively.Supplementary Figure 1Supplementary Figure 2Supplementary figure legends
Authors: Christina Ehrhardt; Thorsten Wolff; Stephan Pleschka; Oliver Planz; Wiebke Beermann; Johannes G Bode; Mirco Schmolke; Stephan Ludwig Journal: J Virol Date: 2007-01-17 Impact factor: 5.103
Authors: W Chen; P A Calvo; D Malide; J Gibbs; U Schubert; I Bacik; S Basta; R O'Neill; J Schickli; P Palese; P Henklein; J R Bennink; J W Yewdell Journal: Nat Med Date: 2001-12 Impact factor: 53.440
Authors: Daniel J Klionsky; Amal Kamal Abdel-Aziz; Sara Abdelfatah; Mahmoud Abdellatif; Asghar Abdoli; Steffen Abel; Hagai Abeliovich; Marie H Abildgaard; Yakubu Princely Abudu; Abraham Acevedo-Arozena; Iannis E Adamopoulos; Khosrow Adeli; Timon E Adolph; Annagrazia Adornetto; Elma Aflaki; Galila Agam; Anupam Agarwal; Bharat B Aggarwal; Maria Agnello; Patrizia Agostinis; Javed N Agrewala; Alexander Agrotis; Patricia V Aguilar; S Tariq Ahmad; Zubair M Ahmed; Ulises Ahumada-Castro; Sonja Aits; Shu Aizawa; Yunus Akkoc; Tonia Akoumianaki; Hafize Aysin Akpinar; Ahmed M Al-Abd; Lina Al-Akra; Abeer Al-Gharaibeh; Moulay A Alaoui-Jamali; Simon Alberti; Elísabet Alcocer-Gómez; Cristiano Alessandri; Muhammad Ali; M Abdul Alim Al-Bari; Saeb Aliwaini; Javad Alizadeh; Eugènia Almacellas; Alexandru Almasan; Alicia Alonso; Guillermo D Alonso; Nihal Altan-Bonnet; Dario C Altieri; Élida M C Álvarez; Sara Alves; Cristine Alves da Costa; Mazen M Alzaharna; Marialaura Amadio; Consuelo Amantini; Cristina Amaral; Susanna Ambrosio; Amal O Amer; Veena Ammanathan; Zhenyi An; Stig U Andersen; Shaida A Andrabi; Magaiver Andrade-Silva; Allen M Andres; Sabrina Angelini; David Ann; Uche C Anozie; Mohammad Y Ansari; Pedro Antas; Adam Antebi; Zuriñe Antón; Tahira Anwar; Lionel Apetoh; Nadezda Apostolova; Toshiyuki Araki; Yasuhiro Araki; Kohei Arasaki; Wagner L Araújo; Jun Araya; Catherine Arden; Maria-Angeles Arévalo; Sandro Arguelles; Esperanza Arias; Jyothi Arikkath; Hirokazu Arimoto; Aileen R Ariosa; Darius Armstrong-James; Laetitia Arnauné-Pelloquin; Angeles Aroca; Daniela S Arroyo; Ivica Arsov; Rubén Artero; Dalia Maria Lucia Asaro; Michael Aschner; Milad Ashrafizadeh; Osnat Ashur-Fabian; Atanas G Atanasov; Alicia K Au; Patrick Auberger; Holger W Auner; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Yenniffer Ávalos; Sanja Aveic; Célia Alexandra Aveleira; Tamar Avin-Wittenberg; Yucel Aydin; Scott Ayton; Srinivas Ayyadevara; Maria Azzopardi; Misuzu Baba; Jonathan M Backer; Steven K Backues; Dong-Hun Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Ahruem Baek; Seung-Hoon Baek; Sung Hee Baek; Giacinto Bagetta; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xiyuan Bai; Yidong Bai; Nandadulal Bairagi; Shounak Baksi; Teresa Balbi; Cosima T Baldari; Walter Balduini; Andrea Ballabio; Maria Ballester; Salma Balazadeh; Rena Balzan; Rina Bandopadhyay; Sreeparna Banerjee; Sulagna Banerjee; Ágnes Bánréti; Yan Bao; Mauricio S Baptista; Alessandra Baracca; Cristiana Barbati; Ariadna Bargiela; Daniela Barilà; Peter G Barlow; Sami J Barmada; Esther Barreiro; George E Barreto; Jiri Bartek; Bonnie Bartel; Alberto Bartolome; Gaurav R Barve; Suresh H Basagoudanavar; Diane C Bassham; Robert C Bast; Alakananda Basu; Henri Batoko; Isabella Batten; Etienne E Baulieu; Bradley L Baumgarner; Jagadeesh Bayry; Rupert Beale; Isabelle Beau; Florian Beaumatin; Luiz R G Bechara; George R Beck; Michael F Beers; Jakob Begun; Christian Behrends; Georg M N Behrens; Roberto Bei; Eloy Bejarano; Shai Bel; Christian Behl; Amine Belaid; Naïma Belgareh-Touzé; Cristina Bellarosa; Francesca Belleudi; Melissa Belló Pérez; Raquel Bello-Morales; Jackeline Soares de Oliveira Beltran; Sebastián Beltran; Doris Mangiaracina Benbrook; Mykolas Bendorius; Bruno A Benitez; Irene Benito-Cuesta; Julien Bensalem; Martin W Berchtold; Sabina Berezowska; Daniele Bergamaschi; Matteo Bergami; Andreas Bergmann; Laura Berliocchi; Clarisse Berlioz-Torrent; Amélie Bernard; Lionel Berthoux; Cagri G Besirli; Sebastien Besteiro; Virginie M Betin; Rudi Beyaert; Jelena S Bezbradica; Kiran Bhaskar; Ingrid Bhatia-Kissova; Resham Bhattacharya; Sujoy Bhattacharya; Shalmoli Bhattacharyya; Md Shenuarin Bhuiyan; Sujit Kumar Bhutia; Lanrong Bi; Xiaolin Bi; Trevor J Biden; Krikor Bijian; Viktor A Billes; Nadine Binart; Claudia Bincoletto; Asa B Birgisdottir; Geir Bjorkoy; Gonzalo Blanco; Ana Blas-Garcia; Janusz Blasiak; Robert Blomgran; Klas Blomgren; Janice S Blum; Emilio Boada-Romero; Mirta Boban; Kathleen Boesze-Battaglia; Philippe Boeuf; Barry Boland; Pascale Bomont; Paolo Bonaldo; Srinivasa Reddy Bonam; Laura Bonfili; Juan S Bonifacino; Brian A Boone; Martin D Bootman; Matteo Bordi; Christoph Borner; Beat C Bornhauser; Gautam Borthakur; Jürgen Bosch; Santanu Bose; Luis M Botana; Juan Botas; Chantal M Boulanger; Michael E Boulton; Mathieu Bourdenx; Benjamin Bourgeois; Nollaig M Bourke; Guilhem Bousquet; Patricia Boya; Peter V Bozhkov; Luiz H M Bozi; Tolga O Bozkurt; Doug E Brackney; Christian H Brandts; Ralf J Braun; Gerhard H Braus; Roberto Bravo-Sagua; José M Bravo-San Pedro; Patrick Brest; Marie-Agnès Bringer; Alfredo Briones-Herrera; V Courtney Broaddus; Peter Brodersen; Jeffrey L Brodsky; Steven L Brody; Paola G Bronson; Jeff M Bronstein; Carolyn N Brown; Rhoderick E Brown; Patricia C Brum; John H Brumell; Nicola Brunetti-Pierri; Daniele Bruno; Robert J Bryson-Richardson; Cecilia Bucci; Carmen Buchrieser; Marta Bueno; Laura Elisa Buitrago-Molina; Simone Buraschi; Shilpa Buch; J Ross Buchan; Erin M Buckingham; Hikmet Budak; Mauricio Budini; Geert Bultynck; Florin Burada; Joseph R Burgoyne; M Isabel Burón; Victor Bustos; Sabrina Büttner; Elena Butturini; Aaron Byrd; Isabel Cabas; Sandra Cabrera-Benitez; Ken Cadwell; Jingjing Cai; Lu Cai; Qian Cai; Montserrat Cairó; Jose A Calbet; Guy A Caldwell; Kim A Caldwell; Jarrod A Call; Riccardo Calvani; Ana C Calvo; Miguel Calvo-Rubio Barrera; Niels Os Camara; Jacques H Camonis; Nadine Camougrand; Michelangelo Campanella; Edward M Campbell; François-Xavier Campbell-Valois; Silvia Campello; Ilaria Campesi; Juliane C Campos; Olivier Camuzard; Jorge Cancino; Danilo Candido de Almeida; Laura Canesi; Isabella Caniggia; Barbara Canonico; Carles Cantí; Bin Cao; Michele Caraglia; Beatriz Caramés; Evie H Carchman; Elena Cardenal-Muñoz; Cesar Cardenas; Luis Cardenas; Sandra M Cardoso; Jennifer S Carew; Georges F Carle; Gillian Carleton; Silvia Carloni; Didac Carmona-Gutierrez; Leticia A Carneiro; Oliana Carnevali; Julian M Carosi; Serena Carra; Alice Carrier; Lucie Carrier; Bernadette Carroll; A Brent Carter; Andreia Neves Carvalho; Magali Casanova; Caty Casas; Josefina Casas; Chiara Cassioli; Eliseo F Castillo; Karen Castillo; Sonia Castillo-Lluva; Francesca Castoldi; Marco Castori; Ariel F Castro; Margarida Castro-Caldas; Javier Castro-Hernandez; Susana Castro-Obregon; Sergio D Catz; Claudia Cavadas; Federica Cavaliere; Gabriella Cavallini; Maria Cavinato; Maria L Cayuela; Paula Cebollada Rica; Valentina Cecarini; Francesco Cecconi; Marzanna Cechowska-Pasko; Simone Cenci; Victòria Ceperuelo-Mallafré; João J Cerqueira; Janete M Cerutti; Davide Cervia; Vildan Bozok Cetintas; Silvia Cetrullo; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Oishee Chakrabarti; Tapas Chakraborty; Trinad Chakraborty; Mounia Chami; Georgios Chamilos; David W Chan; Edmond Y W Chan; Edward D Chan; H Y Edwin Chan; Helen H Chan; Hung Chan; Matthew T V Chan; Yau Sang Chan; Partha K Chandra; Chih-Peng Chang; Chunmei Chang; Hao-Chun Chang; Kai Chang; Jie Chao; Tracey Chapman; Nicolas Charlet-Berguerand; Samrat Chatterjee; Shail K Chaube; Anu Chaudhary; Santosh Chauhan; Edward Chaum; Frédéric Checler; Michael E Cheetham; Chang-Shi Chen; Guang-Chao Chen; Jian-Fu Chen; Liam L Chen; Leilei Chen; Lin Chen; Mingliang Chen; Mu-Kuan Chen; Ning Chen; Quan Chen; Ruey-Hwa Chen; Shi Chen; Wei Chen; Weiqiang Chen; Xin-Ming Chen; Xiong-Wen Chen; Xu Chen; Yan Chen; Ye-Guang Chen; Yingyu Chen; Yongqiang Chen; Yu-Jen Chen; Yue-Qin Chen; Zhefan Stephen Chen; Zhi Chen; Zhi-Hua Chen; Zhijian J Chen; Zhixiang Chen; Hanhua Cheng; Jun Cheng; Shi-Yuan Cheng; Wei Cheng; Xiaodong Cheng; Xiu-Tang Cheng; Yiyun Cheng; Zhiyong Cheng; Zhong Chen; Heesun Cheong; Jit Kong Cheong; Boris V Chernyak; Sara Cherry; Chi Fai Randy Cheung; Chun Hei Antonio Cheung; King-Ho Cheung; Eric Chevet; Richard J Chi; Alan Kwok Shing Chiang; Ferdinando Chiaradonna; Roberto Chiarelli; Mario Chiariello; Nathalia Chica; Susanna Chiocca; Mario Chiong; Shih-Hwa Chiou; Abhilash I Chiramel; Valerio Chiurchiù; Dong-Hyung Cho; Seong-Kyu Choe; Augustine M K Choi; Mary E Choi; Kamalika Roy Choudhury; Norman S Chow; Charleen T Chu; Jason P Chua; John Jia En Chua; Hyewon Chung; Kin Pan Chung; Seockhoon Chung; So-Hyang Chung; Yuen-Li Chung; Valentina Cianfanelli; Iwona A Ciechomska; Mariana Cifuentes; Laura Cinque; Sebahattin Cirak; Mara Cirone; Michael J Clague; Robert Clarke; Emilio Clementi; Eliana M Coccia; Patrice Codogno; Ehud Cohen; Mickael M Cohen; Tania Colasanti; Fiorella Colasuonno; Robert A Colbert; Anna Colell; Miodrag Čolić; Nuria S Coll; Mark O Collins; María I Colombo; Daniel A Colón-Ramos; Lydie Combaret; Sergio Comincini; Márcia R Cominetti; Antonella Consiglio; Andrea Conte; Fabrizio Conti; Viorica Raluca Contu; Mark R Cookson; Kevin M Coombs; Isabelle Coppens; Maria Tiziana Corasaniti; Dale P Corkery; Nils Cordes; Katia Cortese; Maria do Carmo Costa; Sarah Costantino; Paola Costelli; Ana Coto-Montes; Peter J Crack; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Riccardo Cristofani; Tamas Csizmadia; Antonio Cuadrado; Bing Cui; Jun Cui; Yixian Cui; Yong Cui; Emmanuel Culetto; Andrea C Cumino; Andrey V Cybulsky; Mark J Czaja; Stanislaw J Czuczwar; Stefania D'Adamo; Marcello D'Amelio; Daniela D'Arcangelo; Andrew C D'Lugos; Gabriella D'Orazi; James A da Silva; Hormos Salimi Dafsari; Ruben K Dagda; Yasin Dagdas; Maria Daglia; Xiaoxia Dai; Yun Dai; Yuyuan Dai; Jessica Dal Col; Paul Dalhaimer; Luisa Dalla Valle; Tobias Dallenga; Guillaume Dalmasso; Markus Damme; Ilaria Dando; Nico P Dantuma; April L Darling; Hiranmoy Das; Srinivasan Dasarathy; Santosh K Dasari; Srikanta Dash; Oliver Daumke; Adrian N Dauphinee; Jeffrey S Davies; Valeria A Dávila; Roger J Davis; Tanja Davis; Sharadha Dayalan Naidu; Francesca De Amicis; Karolien De Bosscher; Francesca De Felice; Lucia De Franceschi; Chiara De Leonibus; Mayara G de Mattos Barbosa; Guido R Y De Meyer; Angelo De Milito; Cosimo De Nunzio; Clara De Palma; Mauro De Santi; Claudio De Virgilio; Daniela De Zio; Jayanta Debnath; Brian J DeBosch; Jean-Paul Decuypere; Mark A Deehan; Gianluca Deflorian; James DeGregori; Benjamin Dehay; Gabriel Del Rio; Joe R Delaney; Lea M D Delbridge; Elizabeth Delorme-Axford; M Victoria Delpino; Francesca Demarchi; Vilma Dembitz; Nicholas D Demers; Hongbin Deng; Zhiqiang Deng; Joern Dengjel; Paul Dent; Donna Denton; Melvin L DePamphilis; Channing J Der; Vojo Deretic; Albert Descoteaux; Laura Devis; Sushil Devkota; Olivier Devuyst; Grant Dewson; Mahendiran Dharmasivam; Rohan Dhiman; Diego di Bernardo; Manlio Di Cristina; Fabio Di Domenico; Pietro Di Fazio; Alessio Di Fonzo; Giovanni Di Guardo; Gianni M Di Guglielmo; Luca Di Leo; Chiara Di Malta; Alessia Di Nardo; Martina Di Rienzo; Federica Di Sano; George Diallinas; Jiajie Diao; Guillermo Diaz-Araya; Inés Díaz-Laviada; Jared M Dickinson; Marc Diederich; Mélanie Dieudé; Ivan Dikic; Shiping Ding; Wen-Xing Ding; Luciana Dini; Jelena Dinić; Miroslav Dinic; Albena T Dinkova-Kostova; Marc S Dionne; Jörg H W Distler; Abhinav Diwan; Ian M C Dixon; Mojgan Djavaheri-Mergny; Ina Dobrinski; Oxana Dobrovinskaya; Radek Dobrowolski; Renwick C J Dobson; Jelena Đokić; Serap Dokmeci Emre; Massimo Donadelli; Bo Dong; Xiaonan Dong; Zhiwu Dong; Gerald W Dorn Ii; Volker Dotsch; Huan Dou; Juan Dou; Moataz Dowaidar; Sami Dridi; Liat Drucker; Ailian Du; Caigan Du; Guangwei Du; Hai-Ning Du; Li-Lin Du; André du Toit; Shao-Bin Duan; Xiaoqiong Duan; Sónia P Duarte; Anna Dubrovska; Elaine A Dunlop; Nicolas Dupont; Raúl V Durán; Bilikere S Dwarakanath; Sergey A Dyshlovoy; Darius Ebrahimi-Fakhari; Leopold Eckhart; Charles L Edelstein; Thomas Efferth; Eftekhar Eftekharpour; Ludwig Eichinger; Nabil Eid; Tobias Eisenberg; N Tony Eissa; Sanaa Eissa; Miriam Ejarque; Abdeljabar El Andaloussi; Nazira El-Hage; Shahenda El-Naggar; Anna Maria Eleuteri; Eman S El-Shafey; Mohamed Elgendy; Aristides G Eliopoulos; María M Elizalde; Philip M Elks; Hans-Peter Elsasser; Eslam S Elsherbiny; Brooke M Emerling; N C Tolga Emre; Christina H Eng; Nikolai Engedal; Anna-Mart Engelbrecht; Agnete S T Engelsen; Jorrit M Enserink; Ricardo Escalante; Audrey Esclatine; Mafalda Escobar-Henriques; Eeva-Liisa Eskelinen; Lucile Espert; Makandjou-Ola Eusebio; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Francesco Facchiano; Bengt Fadeel; Claudio Fader; Alex C Faesen; W Douglas Fairlie; Alberto Falcó; Bjorn H Falkenburger; Daping Fan; Jie Fan; Yanbo Fan; Evandro F Fang; Yanshan Fang; Yognqi Fang; Manolis Fanto; Tamar Farfel-Becker; Mathias Faure; Gholamreza Fazeli; Anthony O Fedele; Arthur M Feldman; Du Feng; Jiachun Feng; Lifeng Feng; Yibin Feng; Yuchen Feng; Wei Feng; Thais Fenz Araujo; Thomas A Ferguson; Álvaro F Fernández; Jose C Fernandez-Checa; Sonia Fernández-Veledo; Alisdair R Fernie; Anthony W Ferrante; Alessandra Ferraresi; Merari F Ferrari; Julio C B Ferreira; Susan Ferro-Novick; Antonio Figueras; Riccardo Filadi; Nicoletta Filigheddu; Eduardo Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; Vittorio Fineschi; Francesca Finetti; Steven Finkbeiner; Edward A Fisher; Paul B Fisher; Flavio Flamigni; Steven J Fliesler; Trude H Flo; Ida Florance; Oliver Florey; Tullio Florio; Erika Fodor; Carlo Follo; Edward A Fon; Antonella Forlino; Francesco Fornai; Paola Fortini; Anna Fracassi; Alessandro Fraldi; Brunella Franco; Rodrigo Franco; Flavia Franconi; Lisa B Frankel; Scott L Friedman; Leopold F Fröhlich; Gema Frühbeck; Jose M Fuentes; Yukio Fujiki; Naonobu Fujita; Yuuki Fujiwara; Mitsunori Fukuda; Simone Fulda; Luc Furic; Norihiko Furuya; Carmela Fusco; Michaela U Gack; Lidia Gaffke; Sehamuddin Galadari; Alessia Galasso; Maria F Galindo; Sachith Gallolu Kankanamalage; Lorenzo Galluzzi; Vincent Galy; Noor Gammoh; Boyi Gan; Ian G Ganley; Feng Gao; Hui Gao; Minghui Gao; Ping Gao; Shou-Jiang Gao; Wentao Gao; Xiaobo Gao; Ana Garcera; Maria Noé Garcia; Verónica E Garcia; Francisco García-Del Portillo; Vega Garcia-Escudero; Aracely Garcia-Garcia; Marina Garcia-Macia; Diana García-Moreno; Carmen Garcia-Ruiz; Patricia García-Sanz; Abhishek D Garg; Ricardo Gargini; Tina Garofalo; Robert F Garry; Nils C Gassen; Damian Gatica; Liang Ge; Wanzhong Ge; Ruth Geiss-Friedlander; Cecilia Gelfi; Pascal Genschik; Ian E Gentle; Valeria Gerbino; Christoph Gerhardt; Kyla Germain; Marc Germain; David A Gewirtz; Elham Ghasemipour Afshar; Saeid Ghavami; Alessandra Ghigo; Manosij Ghosh; Georgios Giamas; Claudia Giampietri; Alexandra Giatromanolaki; Gary E Gibson; Spencer B Gibson; Vanessa Ginet; Edward Giniger; Carlotta Giorgi; Henrique Girao; Stephen E Girardin; Mridhula Giridharan; Sandy Giuliano; Cecilia Giulivi; Sylvie Giuriato; Julien Giustiniani; Alexander Gluschko; Veit Goder; Alexander Goginashvili; Jakub Golab; David C Goldstone; Anna Golebiewska; Luciana R Gomes; Rodrigo Gomez; Rubén Gómez-Sánchez; Maria Catalina Gomez-Puerto; Raquel Gomez-Sintes; Qingqiu Gong; Felix M Goni; Javier González-Gallego; Tomas Gonzalez-Hernandez; Rosa A Gonzalez-Polo; Jose A Gonzalez-Reyes; Patricia González-Rodríguez; Ing Swie Goping; Marina S Gorbatyuk; Nikolai V Gorbunov; Kıvanç Görgülü; Roxana M Gorojod; Sharon M Gorski; Sandro Goruppi; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Martin Graef; Markus H Gräler; Veronica Granatiero; Daniel Grasso; Joshua P Gray; Douglas R Green; Alexander Greenhough; Stephen L Gregory; Edward F Griffin; Mark W Grinstaff; Frederic Gros; Charles Grose; Angelina S Gross; Florian Gruber; Paolo Grumati; Tilman Grune; Xueyan Gu; Jun-Lin Guan; Carlos M Guardia; Kishore Guda; Flora Guerra; Consuelo Guerri; Prasun Guha; Carlos Guillén; Shashi Gujar; Anna Gukovskaya; Ilya Gukovsky; Jan Gunst; Andreas Günther; Anyonya R Guntur; Chuanyong Guo; Chun Guo; Hongqing Guo; Lian-Wang Guo; Ming Guo; Pawan Gupta; Shashi Kumar Gupta; Swapnil Gupta; Veer Bala Gupta; Vivek Gupta; Asa B Gustafsson; David D Gutterman; Ranjitha H B; Annakaisa Haapasalo; James E Haber; Aleksandra Hać; Shinji Hadano; Anders J Hafrén; Mansour Haidar; Belinda S Hall; Gunnel Halldén; Anne Hamacher-Brady; Andrea Hamann; Maho Hamasaki; Weidong Han; Malene Hansen; Phyllis I Hanson; Zijian Hao; Masaru Harada; Ljubica Harhaji-Trajkovic; Nirmala Hariharan; Nigil Haroon; James Harris; Takafumi Hasegawa; Noor Hasima Nagoor; Jeffrey A Haspel; Volker Haucke; Wayne D Hawkins; Bruce A Hay; Cole M Haynes; Soren B Hayrabedyan; Thomas S Hays; Congcong He; Qin He; Rong-Rong He; You-Wen He; Yu-Ying He; Yasser Heakal; Alexander M Heberle; J Fielding Hejtmancik; Gudmundur Vignir Helgason; Vanessa Henkel; Marc Herb; Alexander Hergovich; Anna Herman-Antosiewicz; Agustín Hernández; Carlos Hernandez; Sergio Hernandez-Diaz; Virginia Hernandez-Gea; Amaury Herpin; Judit Herreros; Javier H Hervás; Daniel Hesselson; Claudio Hetz; Volker T Heussler; Yujiro Higuchi; Sabine Hilfiker; Joseph A Hill; William S Hlavacek; Emmanuel A Ho; Idy H T Ho; Philip Wing-Lok Ho; Shu-Leong Ho; Wan Yun Ho; G Aaron Hobbs; Mark Hochstrasser; Peter H M Hoet; Daniel Hofius; Paul Hofman; Annika Höhn; Carina I Holmberg; Jose R Hombrebueno; Chang-Won Hong Yi-Ren Hong; Lora V Hooper; Thorsten Hoppe; Rastislav Horos; Yujin Hoshida; I-Lun Hsin; Hsin-Yun Hsu; Bing Hu; Dong Hu; Li-Fang Hu; Ming Chang Hu; Ronggui Hu; Wei Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Jinlian Hua; Yingqi Hua; Chongmin Huan; Canhua Huang; Chuanshu Huang; Chuanxin Huang; Chunling Huang; Haishan Huang; Kun Huang; Michael L H Huang; Rui Huang; Shan Huang; Tianzhi Huang; Xing Huang; Yuxiang Jack Huang; Tobias B Huber; Virginie Hubert; Christian A Hubner; Stephanie M Hughes; William E Hughes; Magali Humbert; Gerhard Hummer; James H Hurley; Sabah Hussain; Salik Hussain; Patrick J Hussey; Martina Hutabarat; Hui-Yun Hwang; Seungmin Hwang; Antonio Ieni; Fumiyo Ikeda; Yusuke Imagawa; Yuzuru Imai; Carol Imbriano; Masaya Imoto; Denise M Inman; Ken Inoki; Juan Iovanna; Renato V Iozzo; Giuseppe Ippolito; Javier E Irazoqui; Pablo Iribarren; Mohd Ishaq; Makoto Ishikawa; Nestor Ishimwe; Ciro Isidoro; Nahed Ismail; Shohreh Issazadeh-Navikas; Eisuke Itakura; Daisuke Ito; Davor Ivankovic; Saška Ivanova; Anand Krishnan V Iyer; José M Izquierdo; Masanori Izumi; Marja Jäättelä; Majid Sakhi Jabir; William T Jackson; Nadia Jacobo-Herrera; Anne-Claire Jacomin; Elise Jacquin; Pooja Jadiya; Hartmut Jaeschke; Chinnaswamy Jagannath; Arjen J Jakobi; Johan Jakobsson; Bassam Janji; Pidder Jansen-Dürr; Patric J Jansson; Jonathan Jantsch; Sławomir Januszewski; Alagie Jassey; Steve Jean; Hélène Jeltsch-David; Pavla Jendelova; Andreas Jenny; Thomas E Jensen; Niels Jessen; Jenna L Jewell; Jing Ji; Lijun Jia; Rui Jia; Liwen Jiang; Qing Jiang; Richeng Jiang; Teng Jiang; Xuejun Jiang; Yu Jiang; Maria Jimenez-Sanchez; Eun-Jung Jin; Fengyan Jin; Hongchuan Jin; Li Jin; Luqi Jin; Meiyan Jin; Si Jin; Eun-Kyeong Jo; Carine Joffre; Terje Johansen; Gail V W Johnson; Simon A Johnston; Eija Jokitalo; Mohit Kumar Jolly; Leo A B Joosten; Joaquin Jordan; Bertrand Joseph; Dianwen Ju; Jeong-Sun Ju; Jingfang Ju; Esmeralda Juárez; Delphine Judith; Gábor Juhász; Youngsoo Jun; Chang Hwa Jung; Sung-Chul Jung; Yong Keun Jung; Heinz Jungbluth; Johannes Jungverdorben; Steffen Just; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Daniel Kaganovich; Alon Kahana; Renate Kain; Shinjo Kajimura; Maria Kalamvoki; Manjula Kalia; Danuta S Kalinowski; Nina Kaludercic; Ioanna Kalvari; Joanna Kaminska; Vitaliy O Kaminskyy; Hiromitsu Kanamori; Keizo Kanasaki; Chanhee Kang; Rui Kang; Sang Sun Kang; Senthilvelrajan Kaniyappan; Tomotake Kanki; Thirumala-Devi Kanneganti; Anumantha G Kanthasamy; Arthi Kanthasamy; Marc Kantorow; Orsolya Kapuy; Michalis V Karamouzis; Md Razaul Karim; Parimal Karmakar; Rajesh G Katare; Masaru Kato; Stefan H E Kaufmann; Anu Kauppinen; Gur P Kaushal; Susmita Kaushik; Kiyoshi Kawasaki; Kemal Kazan; Po-Yuan Ke; Damien J Keating; Ursula Keber; John H Kehrl; Kate E Keller; Christian W Keller; Jongsook Kim Kemper; Candia M Kenific; Oliver Kepp; Stephanie Kermorgant; Andreas Kern; Robin Ketteler; Tom G Keulers; Boris Khalfin; Hany Khalil; Bilon Khambu; Shahid Y Khan; Vinoth Kumar Megraj Khandelwal; Rekha Khandia; Widuri Kho; Noopur V Khobrekar; Sataree Khuansuwan; Mukhran Khundadze; Samuel A Killackey; Dasol Kim; Deok Ryong Kim; Do-Hyung Kim; Dong-Eun Kim; Eun Young Kim; Eun-Kyoung Kim; Hak-Rim Kim; Hee-Sik Kim; Jeong Hun Kim; Jin Kyung Kim; Jin-Hoi Kim; Joungmok Kim; Ju Hwan Kim; Keun Il Kim; Peter K Kim; Seong-Jun Kim; Scot R Kimball; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Matthew A King; Kerri J Kinghorn; Conan G Kinsey; Vladimir Kirkin; Lorrie A Kirshenbaum; Sergey L Kiselev; Shuji Kishi; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Richard N Kitsis; Josef T Kittler; Ole Kjaerulff; Peter S Klein; Thomas Klopstock; Jochen Klucken; Helene Knævelsrud; Roland L Knorr; Ben C B Ko; Fred Ko; Jiunn-Liang Ko; Hotaka Kobayashi; Satoru Kobayashi; Ina Koch; Jan C Koch; Ulrich Koenig; Donat Kögel; Young Ho Koh; Masato Koike; Sepp D Kohlwein; Nur M Kocaturk; Masaaki Komatsu; Jeannette König; Toru Kono; Benjamin T Kopp; Tamas Korcsmaros; Gözde Korkmaz; Viktor I Korolchuk; Mónica Suárez Korsnes; Ali Koskela; Janaiah Kota; Yaichiro Kotake; Monica L Kotler; Yanjun Kou; Michael I Koukourakis; Evangelos Koustas; Attila L Kovacs; Tibor Kovács; Daisuke Koya; Tomohiro Kozako; Claudine Kraft; Dimitri Krainc; Helmut Krämer; Anna D Krasnodembskaya; Carole Kretz-Remy; Guido Kroemer; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Sabine Kuenen; Lars Kuerschner; Thomas Kukar; Ajay Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Sharad Kumar; Shinji Kume; Caroline Kumsta; Chanakya N Kundu; Mondira Kundu; Ajaikumar B Kunnumakkara; Lukasz Kurgan; Tatiana G Kutateladze; Ozlem Kutlu; SeongAe Kwak; Ho Jeong Kwon; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert La Spada; Patrick Labonté; Sylvain Ladoire; Ilaria Laface; Frank Lafont; Diane C Lagace; Vikramjit Lahiri; Zhibing Lai; Angela S Laird; Aparna Lakkaraju; Trond Lamark; Sheng-Hui Lan; Ane Landajuela; Darius J R Lane; Jon D Lane; Charles H Lang; Carsten Lange; Ülo Langel; Rupert Langer; Pierre Lapaquette; Jocelyn Laporte; Nicholas F LaRusso; Isabel Lastres-Becker; Wilson Chun Yu Lau; Gordon W Laurie; Sergio Lavandero; Betty Yuen Kwan Law; Helen Ka-Wai Law; Rob Layfield; Weidong Le; Herve Le Stunff; Alexandre Y Leary; Jean-Jacques Lebrun; Lionel Y W Leck; Jean-Philippe Leduc-Gaudet; Changwook Lee; Chung-Pei Lee; Da-Hye Lee; Edward B Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Heung Kyu Lee; Jae Man Lee; Jason S Lee; Jin-A Lee; Joo-Yong Lee; Jun Hee Lee; Michael Lee; Min Goo Lee; Min Jae Lee; Myung-Shik Lee; Sang Yoon Lee; Seung-Jae Lee; Stella Y Lee; Sung Bae Lee; Won Hee Lee; Ying-Ray Lee; Yong-Ho Lee; Youngil Lee; Christophe Lefebvre; Renaud Legouis; Yu L Lei; Yuchen Lei; Sergey Leikin; Gerd Leitinger; Leticia Lemus; Shuilong Leng; Olivia Lenoir; Guido Lenz; Heinz Josef Lenz; Paola Lenzi; Yolanda León; Andréia M Leopoldino; Christoph Leschczyk; Stina Leskelä; Elisabeth Letellier; Chi-Ting Leung; Po Sing Leung; Jeremy S Leventhal; Beth Levine; Patrick A Lewis; Klaus Ley; Bin Li; Da-Qiang Li; Jianming Li; Jing Li; Jiong Li; Ke Li; Liwu Li; Mei Li; Min Li; Min Li; Ming Li; Mingchuan Li; Pin-Lan Li; Ming-Qing Li; Qing Li; Sheng Li; Tiangang Li; Wei Li; Wenming Li; Xue Li; Yi-Ping Li; Yuan Li; Zhiqiang Li; Zhiyong Li; Zhiyuan Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Weicheng Liang; Yongheng Liang; YongTian Liang; Guanghong Liao; Lujian Liao; Mingzhi Liao; Yung-Feng Liao; Mariangela Librizzi; Pearl P Y Lie; Mary A Lilly; Hyunjung J Lim; Thania R R Lima; Federica Limana; Chao Lin; Chih-Wen Lin; Dar-Shong Lin; Fu-Cheng Lin; Jiandie D Lin; Kurt M Lin; Kwang-Huei Lin; Liang-Tzung Lin; Pei-Hui Lin; Qiong Lin; Shaofeng Lin; Su-Ju Lin; Wenyu Lin; Xueying Lin; Yao-Xin Lin; Yee-Shin Lin; Rafael Linden; Paula Lindner; Shuo-Chien Ling; Paul Lingor; Amelia K Linnemann; Yih-Cherng Liou; Marta M Lipinski; Saška Lipovšek; Vitor A Lira; Natalia Lisiak; Paloma B Liton; Chao Liu; Ching-Hsuan Liu; Chun-Feng Liu; Cui Hua Liu; Fang Liu; Hao Liu; Hsiao-Sheng Liu; Hua-Feng Liu; Huifang Liu; Jia Liu; Jing Liu; Julia Liu; Leyuan Liu; Longhua Liu; Meilian Liu; Qin Liu; Wei Liu; Wende Liu; Xiao-Hong Liu; Xiaodong Liu; Xingguo Liu; Xu Liu; Xuedong Liu; Yanfen Liu; Yang Liu; Yang Liu; Yueyang Liu; Yule Liu; J Andrew Livingston; Gerard Lizard; Jose M Lizcano; Senka Ljubojevic-Holzer; Matilde E LLeonart; David Llobet-Navàs; Alicia Llorente; Chih Hung Lo; Damián Lobato-Márquez; Qi Long; Yun Chau Long; Ben Loos; Julia A Loos; Manuela G López; Guillermo López-Doménech; José Antonio López-Guerrero; Ana T López-Jiménez; Óscar López-Pérez; Israel López-Valero; Magdalena J Lorenowicz; Mar Lorente; Peter Lorincz; Laura Lossi; Sophie Lotersztajn; Penny E Lovat; Jonathan F Lovell; Alenka Lovy; Péter Lőw; Guang Lu; Haocheng Lu; Jia-Hong Lu; Jin-Jian Lu; Mengji Lu; Shuyan Lu; Alessandro Luciani; John M Lucocq; Paula Ludovico; Micah A Luftig; Morten Luhr; Diego Luis-Ravelo; Julian J Lum; Liany Luna-Dulcey; Anders H Lund; Viktor K Lund; Jan D Lünemann; Patrick Lüningschrör; Honglin Luo; Rongcan Luo; Shouqing Luo; Zhi Luo; Claudio Luparello; Bernhard Lüscher; Luan Luu; Alex Lyakhovich; Konstantin G Lyamzaev; Alf Håkon Lystad; Lyubomyr Lytvynchuk; Alvin C Ma; Changle Ma; Mengxiao Ma; Ning-Fang Ma; Quan-Hong Ma; Xinliang Ma; Yueyun Ma; Zhenyi Ma; Ormond A MacDougald; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; Sandra Maday; Frank Madeo; Muniswamy Madesh; Tobias Madl; Julio Madrigal-Matute; Akiko Maeda; Yasuhiro Maejima; Marta Magarinos; Poornima Mahavadi; Emiliano Maiani; Kenneth Maiese; Panchanan Maiti; Maria Chiara Maiuri; Barbara Majello; Michael B Major; Elena Makareeva; Fayaz Malik; Karthik Mallilankaraman; Walter Malorni; Alina Maloyan; Najiba Mammadova; Gene Chi Wai Man; Federico Manai; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Masoud H Manjili; Ravi Manjithaya; Patricio Manque; Bella B Manshian; Raquel Manzano; Claudia Manzoni; Kai Mao; Cinzia Marchese; Sandrine Marchetti; Anna Maria Marconi; Fabrizio Marcucci; Stefania Mardente; Olga A Mareninova; Marta Margeta; Muriel Mari; Sara Marinelli; Oliviero Marinelli; Guillermo Mariño; Sofia Mariotto; Richard S Marshall; Mark R Marten; Sascha Martens; Alexandre P J Martin; Katie R Martin; Sara Martin; Shaun Martin; Adrián Martín-Segura; Miguel A Martín-Acebes; Inmaculada Martin-Burriel; Marcos Martin-Rincon; Paloma Martin-Sanz; José A Martina; Wim Martinet; Aitor Martinez; Ana Martinez; Jennifer Martinez; Moises Martinez Velazquez; Nuria Martinez-Lopez; Marta Martinez-Vicente; Daniel O Martins; Joilson O Martins; Waleska K Martins; Tania Martins-Marques; Emanuele Marzetti; Shashank Masaldan; Celine Masclaux-Daubresse; Douglas G Mashek; Valentina Massa; Lourdes Massieu; Glenn R Masson; Laura Masuelli; Anatoliy I Masyuk; Tetyana V Masyuk; Paola Matarrese; Ander Matheu; Satoaki Matoba; Sachiko Matsuzaki; Pamela Mattar; Alessandro Matte; Domenico Mattoscio; José L Mauriz; Mario Mauthe; Caroline Mauvezin; Emanual Maverakis; Paola Maycotte; Johanna Mayer; Gianluigi Mazzoccoli; Cristina Mazzoni; Joseph R Mazzulli; Nami McCarty; Christine McDonald; Mitchell R McGill; Sharon L McKenna; BethAnn McLaughlin; Fionn McLoughlin; Mark A McNiven; Thomas G McWilliams; Fatima Mechta-Grigoriou; Tania Catarina Medeiros; Diego L Medina; Lynn A Megeney; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Alfred J Meijer; Annemarie H Meijer; Jakob Mejlvang; Alicia Meléndez; Annette Melk; Gonen Memisoglu; Alexandrina F Mendes; Delong Meng; Fei Meng; Tian Meng; Rubem Menna-Barreto; Manoj B Menon; Carol Mercer; Anne E Mercier; Jean-Louis Mergny; Adalberto Merighi; Seth D Merkley; Giuseppe Merla; Volker Meske; Ana Cecilia Mestre; Shree Padma Metur; Christian Meyer; Hemmo Meyer; Wenyi Mi; Jeanne Mialet-Perez; Junying Miao; Lucia Micale; Yasuo Miki; Enrico Milan; Małgorzata Milczarek; Dana L Miller; Samuel I Miller; Silke Miller; Steven W Millward; Ira Milosevic; Elena A Minina; Hamed Mirzaei; Hamid Reza Mirzaei; Mehdi Mirzaei; Amit Mishra; Nandita Mishra; Paras Kumar Mishra; Maja Misirkic Marjanovic; Roberta Misasi; Amit Misra; Gabriella Misso; Claire Mitchell; Geraldine Mitou; Tetsuji Miura; Shigeki Miyamoto; Makoto Miyazaki; Mitsunori Miyazaki; Taiga Miyazaki; Keisuke Miyazawa; Noboru Mizushima; Trine H Mogensen; Baharia Mograbi; Reza Mohammadinejad; Yasir Mohamud; Abhishek Mohanty; Sipra Mohapatra; Torsten Möhlmann; Asif Mohmmed; Anna Moles; Kelle H Moley; Maurizio Molinari; Vincenzo Mollace; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Costanza Montagna; Mervyn J Monteiro; Andrea Montella; L Ruth Montes; Barbara Montico; Vinod K Mony; Giacomo Monzio Compagnoni; Michael N Moore; Mohammad A Moosavi; Ana L Mora; Marina Mora; David Morales-Alamo; Rosario Moratalla; Paula I Moreira; Elena Morelli; Sandra Moreno; Daniel Moreno-Blas; Viviana Moresi; Benjamin Morga; Alwena H Morgan; Fabrice Morin; Hideaki Morishita; Orson L Moritz; Mariko Moriyama; Yuji Moriyasu; Manuela Morleo; Eugenia Morselli; Jose F Moruno-Manchon; Jorge Moscat; Serge Mostowy; Elisa Motori; Andrea Felinto Moura; Naima Moustaid-Moussa; Maria Mrakovcic; Gabriel Muciño-Hernández; Anupam Mukherjee; Subhadip Mukhopadhyay; Jean M Mulcahy Levy; Victoriano Mulero; Sylviane Muller; Christian Münch; Ashok Munjal; Pura Munoz-Canoves; Teresa Muñoz-Galdeano; Christian Münz; Tomokazu Murakawa; Claudia Muratori; Brona M Murphy; J Patrick Murphy; Aditya Murthy; Timo T Myöhänen; Indira U Mysorekar; Jennifer Mytych; Seyed Mohammad Nabavi; Massimo Nabissi; Péter Nagy; Jihoon Nah; Aimable Nahimana; Ichiro Nakagawa; Ken Nakamura; Hitoshi Nakatogawa; Shyam S Nandi; Meera Nanjundan; Monica Nanni; Gennaro Napolitano; Roberta Nardacci; Masashi Narita; Melissa Nassif; Ilana Nathan; Manabu Natsumeda; Ryno J Naude; Christin Naumann; Olaia Naveiras; Fatemeh Navid; Steffan T Nawrocki; Taras Y Nazarko; Francesca Nazio; Florentina Negoita; Thomas Neill; Amanda L Neisch; Luca M Neri; Mihai G Netea; Patrick Neubert; Thomas P Neufeld; Dietbert Neumann; Albert Neutzner; Phillip T Newton; Paul A Ney; Ioannis P Nezis; Charlene C W Ng; Tzi Bun Ng; Hang T T Nguyen; Long T Nguyen; Hong-Min Ni; Clíona Ní Cheallaigh; Zhenhong Ni; M Celeste Nicolao; Francesco Nicoli; Manuel Nieto-Diaz; Per Nilsson; Shunbin Ning; Rituraj Niranjan; Hiroshi Nishimune; Mireia Niso-Santano; Ralph A Nixon; Annalisa Nobili; Clevio Nobrega; Takeshi Noda; Uxía Nogueira-Recalde; Trevor M Nolan; Ivan Nombela; Ivana Novak; Beatriz Novoa; Takashi Nozawa; Nobuyuki Nukina; Carmen Nussbaum-Krammer; Jesper Nylandsted; Tracey R O'Donovan; Seónadh M O'Leary; Eyleen J O'Rourke; Mary P O'Sullivan; Timothy E O'Sullivan; Salvatore Oddo; Ina Oehme; Michinaga Ogawa; Eric Ogier-Denis; Margret H Ogmundsdottir; Besim Ogretmen; Goo Taeg Oh; Seon-Hee Oh; Young J Oh; Takashi Ohama; Yohei Ohashi; Masaki Ohmuraya; Vasileios Oikonomou; Rani Ojha; Koji Okamoto; Hitoshi Okazawa; Masahide Oku; Sara Oliván; Jorge M A Oliveira; Michael Ollmann; James A Olzmann; Shakib Omari; M Bishr Omary; Gizem Önal; Martin Ondrej; Sang-Bing Ong; Sang-Ging Ong; Anna Onnis; Juan A Orellana; Sara Orellana-Muñoz; Maria Del Mar Ortega-Villaizan; Xilma R Ortiz-Gonzalez; Elena Ortona; Heinz D Osiewacz; Abdel-Hamid K Osman; Rosario Osta; Marisa S Otegui; Kinya Otsu; Christiane Ott; Luisa Ottobrini; Jing-Hsiung James Ou; Tiago F Outeiro; Inger Oynebraten; Melek Ozturk; Gilles Pagès; Susanta Pahari; Marta Pajares; Utpal B Pajvani; Rituraj Pal; Simona Paladino; Nicolas Pallet; Michela Palmieri; Giuseppe Palmisano; Camilla Palumbo; Francesco Pampaloni; Lifeng Pan; Qingjun Pan; Wenliang Pan; Xin Pan; Ganna Panasyuk; Rahul Pandey; Udai B Pandey; Vrajesh Pandya; Francesco Paneni; Shirley Y Pang; Elisa Panzarini; Daniela L Papademetrio; Elena Papaleo; Daniel Papinski; Diana Papp; Eun Chan Park; Hwan Tae Park; Ji-Man Park; Jong-In Park; Joon Tae Park; Junsoo Park; Sang Chul Park; Sang-Youel Park; Abraham H Parola; Jan B Parys; Adrien Pasquier; Benoit Pasquier; João F Passos; Nunzia Pastore; Hemal H Patel; Daniel Patschan; Sophie Pattingre; Gustavo Pedraza-Alva; Jose Pedraza-Chaverri; Zully Pedrozo; Gang Pei; Jianming Pei; Hadas Peled-Zehavi; Joaquín M Pellegrini; Joffrey Pelletier; Miguel A Peñalva; Di Peng; Ying Peng; Fabio Penna; Maria Pennuto; Francesca Pentimalli; Cláudia Mf Pereira; Gustavo J S Pereira; Lilian C Pereira; Luis Pereira de Almeida; Nirma D Perera; Ángel Pérez-Lara; Ana B Perez-Oliva; María Esther Pérez-Pérez; Palsamy Periyasamy; Andras Perl; Cristiana Perrotta; Ida Perrotta; Richard G Pestell; Morten Petersen; Irina Petrache; Goran Petrovski; Thorsten Pfirrmann; Astrid S Pfister; Jennifer A Philips; Huifeng Pi; Anna Picca; Alicia M Pickrell; Sandy Picot; Giovanna M Pierantoni; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Karolina Pierzynowska; Federico Pietrocola; Miroslawa Pietruczuk; Claudio Pignata; Felipe X Pimentel-Muiños; Mario Pinar; Roberta O Pinheiro; Ronit Pinkas-Kramarski; Paolo Pinton; Karolina Pircs; Sujan Piya; Paola Pizzo; Theo S Plantinga; Harald W Platta; Ainhoa Plaza-Zabala; Markus Plomann; Egor Y Plotnikov; Helene Plun-Favreau; Ryszard Pluta; Roger Pocock; Stefanie Pöggeler; Christian Pohl; Marc Poirot; Angelo Poletti; Marisa Ponpuak; Hana Popelka; Blagovesta Popova; Helena Porta; Soledad Porte Alcon; Eliana Portilla-Fernandez; Martin Post; Malia B Potts; Joanna Poulton; Ted Powers; Veena Prahlad; Tomasz K Prajsnar; Domenico Praticò; Rosaria Prencipe; Muriel Priault; Tassula Proikas-Cezanne; Vasilis J Promponas; Christopher G Proud; Rosa Puertollano; Luigi Puglielli; Thomas Pulinilkunnil; Deepika Puri; Rajat Puri; Julien Puyal; Xiaopeng Qi; Yongmei Qi; Wenbin Qian; Lei Qiang; Yu Qiu; Joe Quadrilatero; Jorge Quarleri; Nina Raben; Hannah Rabinowich; Debora Ragona; Michael J Ragusa; Nader Rahimi; Marveh Rahmati; Valeria Raia; Nuno Raimundo; Namakkal-Soorappan Rajasekaran; Sriganesh Ramachandra Rao; Abdelhaq Rami; Ignacio Ramírez-Pardo; David B Ramsden; Felix Randow; Pundi N Rangarajan; Danilo Ranieri; Hai Rao; Lang Rao; Rekha Rao; Sumit Rathore; J Arjuna Ratnayaka; Edward A Ratovitski; Palaniyandi Ravanan; Gloria Ravegnini; Swapan K Ray; Babak Razani; Vito Rebecca; Fulvio Reggiori; Anne Régnier-Vigouroux; Andreas S Reichert; David Reigada; Jan H Reiling; Theo Rein; Siegfried Reipert; Rokeya Sultana Rekha; Hongmei Ren; Jun Ren; Weichao Ren; Tristan Renault; Giorgia Renga; Karen Reue; Kim Rewitz; Bruna Ribeiro de Andrade Ramos; S Amer Riazuddin; Teresa M Ribeiro-Rodrigues; Jean-Ehrland Ricci; Romeo Ricci; Victoria Riccio; Des R Richardson; Yasuko Rikihisa; Makarand V Risbud; Ruth M Risueño; Konstantinos Ritis; Salvatore Rizza; Rosario Rizzuto; Helen C Roberts; Luke D Roberts; Katherine J Robinson; Maria Carmela Roccheri; Stephane Rocchi; George G Rodney; Tiago Rodrigues; Vagner Ramon Rodrigues Silva; Amaia Rodriguez; Ruth Rodriguez-Barrueco; Nieves Rodriguez-Henche; Humberto Rodriguez-Rocha; Jeroen Roelofs; Robert S Rogers; Vladimir V Rogov; Ana I Rojo; Krzysztof Rolka; Vanina Romanello; Luigina Romani; Alessandra Romano; Patricia S Romano; David Romeo-Guitart; Luis C Romero; Montserrat Romero; Joseph C Roney; Christopher Rongo; Sante Roperto; Mathias T Rosenfeldt; Philip Rosenstiel; Anne G Rosenwald; Kevin A Roth; Lynn Roth; Steven Roth; Kasper M A Rouschop; Benoit D Roussel; Sophie Roux; Patrizia Rovere-Querini; Ajit Roy; Aurore Rozieres; Diego Ruano; David C Rubinsztein; Maria P Rubtsova; Klaus Ruckdeschel; Christoph Ruckenstuhl; Emil Rudolf; Rüdiger Rudolf; Alessandra Ruggieri; Avnika Ashok Ruparelia; Paola Rusmini; Ryan R Russell; Gian Luigi Russo; Maria Russo; Rossella Russo; Oxana O Ryabaya; Kevin M Ryan; Kwon-Yul Ryu; Maria Sabater-Arcis; Ulka Sachdev; Michael Sacher; Carsten Sachse; Abhishek Sadhu; Junichi Sadoshima; Nathaniel Safren; Paul Saftig; Antonia P Sagona; Gaurav Sahay; Amirhossein Sahebkar; Mustafa Sahin; Ozgur Sahin; Sumit Sahni; Nayuta Saito; Shigeru Saito; Tsunenori Saito; Ryohei Sakai; Yasuyoshi Sakai; Jun-Ichi Sakamaki; Kalle Saksela; Gloria Salazar; Anna Salazar-Degracia; Ghasem H Salekdeh; Ashok K Saluja; Belém Sampaio-Marques; Maria Cecilia Sanchez; Jose A Sanchez-Alcazar; Victoria Sanchez-Vera; Vanessa Sancho-Shimizu; J Thomas Sanderson; Marco Sandri; Stefano Santaguida; Laura Santambrogio; Magda M Santana; Giorgio Santoni; Alberto Sanz; Pascual Sanz; Shweta Saran; Marco Sardiello; Timothy J Sargeant; Apurva Sarin; Chinmoy Sarkar; Sovan Sarkar; Maria-Rosa Sarrias; Surajit Sarkar; Dipanka Tanu Sarmah; Jaakko Sarparanta; Aishwarya Sathyanarayan; Ranganayaki Sathyanarayanan; K Matthew Scaglione; Francesca Scatozza; Liliana Schaefer; Zachary T Schafer; Ulrich E Schaible; Anthony H V Schapira; Michael Scharl; Hermann M Schatzl; Catherine H Schein; Wiep Scheper; David Scheuring; Maria Vittoria Schiaffino; Monica Schiappacassi; Rainer Schindl; Uwe Schlattner; Oliver Schmidt; Roland Schmitt; Stephen D Schmidt; Ingo Schmitz; Eran Schmukler; Anja Schneider; Bianca E Schneider; Romana Schober; Alejandra C Schoijet; Micah B Schott; Michael Schramm; Bernd Schröder; Kai Schuh; Christoph Schüller; Ryan J Schulze; Lea Schürmanns; Jens C Schwamborn; Melanie Schwarten; Filippo Scialo; Sebastiano Sciarretta; Melanie J Scott; Kathleen W Scotto; A Ivana Scovassi; Andrea Scrima; Aurora Scrivo; David Sebastian; Salwa Sebti; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Iban Seiliez; Ekihiro Seki; Scott B Selleck; Frank W Sellke; Joshua T Selsby; Michael Sendtner; Serif Senturk; Elena Seranova; Consolato Sergi; Ruth Serra-Moreno; Hiromi Sesaki; Carmine Settembre; Subba Rao Gangi Setty; Gianluca Sgarbi; Ou Sha; John J Shacka; Javeed A Shah; Dantong Shang; Changshun Shao; Feng Shao; Soroush Sharbati; Lisa M Sharkey; Dipali Sharma; Gaurav Sharma; Kulbhushan Sharma; Pawan Sharma; Surendra Sharma; Han-Ming Shen; Hongtao Shen; Jiangang Shen; Ming Shen; Weili Shen; Zheni Shen; Rui Sheng; Zhi Sheng; Zu-Hang Sheng; Jianjian Shi; Xiaobing Shi; Ying-Hong Shi; Kahori Shiba-Fukushima; Jeng-Jer Shieh; Yohta Shimada; Shigeomi Shimizu; Makoto Shimozawa; Takahiro Shintani; Christopher J Shoemaker; Shahla Shojaei; Ikuo Shoji; Bhupendra V Shravage; Viji Shridhar; Chih-Wen Shu; Hong-Bing Shu; Ke Shui; Arvind K Shukla; Timothy E Shutt; Valentina Sica; Aleem Siddiqui; Amanda Sierra; Virginia Sierra-Torre; Santiago Signorelli; Payel Sil; Bruno J de Andrade Silva; Johnatas D Silva; Eduardo Silva-Pavez; Sandrine Silvente-Poirot; Rachel E Simmonds; Anna Katharina Simon; Hans-Uwe Simon; Matias Simons; Anurag Singh; Lalit P Singh; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Sudha B Singh; Sunaina Singh; Surinder Pal Singh; Debasish Sinha; Rohit Anthony Sinha; Sangita Sinha; Agnieszka Sirko; Kapil Sirohi; Efthimios L Sivridis; Panagiotis Skendros; Aleksandra Skirycz; Iva Slaninová; Soraya S Smaili; Andrei Smertenko; Matthew D Smith; Stefaan J Soenen; Eun Jung Sohn; Sophia P M Sok; Giancarlo Solaini; Thierry Soldati; Scott A Soleimanpour; Rosa M Soler; Alexei Solovchenko; Jason A Somarelli; Avinash Sonawane; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Kunhua Song; Zhiyin Song; Leandro R Soria; Maurizio Sorice; Alexander A Soukas; Sandra-Fausia Soukup; Diana Sousa; Nadia Sousa; Paul A Spagnuolo; Stephen A Spector; M M Srinivas Bharath; Daret St Clair; Venturina Stagni; Leopoldo Staiano; Clint A Stalnecker; Metodi V Stankov; Peter B Stathopulos; Katja Stefan; Sven Marcel Stefan; Leonidas Stefanis; Joan S Steffan; Alexander Steinkasserer; Harald Stenmark; Jared Sterneckert; Craig Stevens; Veronika Stoka; Stephan Storch; Björn Stork; Flavie Strappazzon; Anne Marie Strohecker; Dwayne G Stupack; Huanxing Su; Ling-Yan Su; Longxiang Su; Ana M Suarez-Fontes; Carlos S Subauste; Selvakumar Subbian; Paula V Subirada; Ganapasam Sudhandiran; Carolyn M Sue; Xinbing Sui; Corey Summers; Guangchao Sun; Jun Sun; Kang Sun; Meng-Xiang Sun; Qiming Sun; Yi Sun; Zhongjie Sun; Karen K S Sunahara; Eva Sundberg; Katalin Susztak; Peter Sutovsky; Hidekazu Suzuki; Gary Sweeney; J David Symons; Stephen Cho Wing Sze; Nathaniel J Szewczyk; Anna Tabęcka-Łonczynska; Claudio Tabolacci; Frank Tacke; Heinrich Taegtmeyer; Marco Tafani; Mitsuo Tagaya; Haoran Tai; Stephen W G Tait; Yoshinori Takahashi; Szabolcs Takats; Priti Talwar; Chit Tam; Shing Yau Tam; Davide Tampellini; Atsushi Tamura; Chong Teik Tan; Eng-King Tan; Ya-Qin Tan; Masaki Tanaka; Motomasa Tanaka; Daolin Tang; Jingfeng Tang; Tie-Shan Tang; Isei Tanida; Zhipeng Tao; Mohammed Taouis; Lars Tatenhorst; Nektarios Tavernarakis; Allen Taylor; Gregory A Taylor; Joan M Taylor; Elena Tchetina; Andrew R Tee; Irmgard Tegeder; David Teis; Natercia Teixeira; Fatima Teixeira-Clerc; Kumsal A Tekirdag; Tewin Tencomnao; Sandra Tenreiro; Alexei V Tepikin; Pilar S Testillano; Gianluca Tettamanti; Pierre-Louis Tharaux; Kathrin Thedieck; Arvind A Thekkinghat; Stefano Thellung; Josephine W Thinwa; V P Thirumalaikumar; Sufi Mary Thomas; Paul G Thomes; Andrew Thorburn; Lipi Thukral; Thomas Thum; Michael Thumm; Ling Tian; Ales Tichy; Andreas Till; Vincent Timmerman; Vladimir I Titorenko; Sokol V Todi; Krassimira Todorova; Janne M Toivonen; Luana Tomaipitinca; Dhanendra Tomar; Cristina Tomas-Zapico; Sergej Tomić; Benjamin Chun-Kit Tong; Chao Tong; Xin Tong; Sharon A Tooze; Maria L Torgersen; Satoru Torii; Liliana Torres-López; Alicia Torriglia; Christina G Towers; Roberto Towns; Shinya Toyokuni; Vladimir Trajkovic; Donatella Tramontano; Quynh-Giao Tran; Leonardo H Travassos; Charles B Trelford; Shirley Tremel; Ioannis P Trougakos; Betty P Tsao; Mario P Tschan; Hung-Fat Tse; Tak Fu Tse; Hitoshi Tsugawa; Andrey S Tsvetkov; David A Tumbarello; Yasin Tumtas; María J Tuñón; Sandra Turcotte; Boris Turk; Vito Turk; Bradley J Turner; Richard I Tuxworth; Jessica K Tyler; Elena V Tyutereva; Yasuo Uchiyama; Aslihan Ugun-Klusek; Holm H Uhlig; Marzena Ułamek-Kozioł; Ilya V Ulasov; Midori Umekawa; Christian Ungermann; Rei Unno; Sylvie Urbe; Elisabet Uribe-Carretero; Suayib Üstün; Vladimir N Uversky; Thomas Vaccari; Maria I Vaccaro; Björn F Vahsen; Helin Vakifahmetoglu-Norberg; Rut Valdor; Maria J Valente; Ayelén Valko; Richard B Vallee; Angela M Valverde; Greet Van den Berghe; Stijn van der Veen; Luc Van Kaer; Jorg van Loosdregt; Sjoerd J L van Wijk; Wim Vandenberghe; Ilse Vanhorebeek; Marcos A Vannier-Santos; Nicola Vannini; M Cristina Vanrell; Chiara Vantaggiato; Gabriele Varano; Isabel Varela-Nieto; Máté Varga; M Helena Vasconcelos; Somya Vats; Demetrios G Vavvas; Ignacio Vega-Naredo; Silvia Vega-Rubin-de-Celis; Guillermo Velasco; Ariadna P Velázquez; Tibor Vellai; Edo Vellenga; Francesca Velotti; Mireille Verdier; Panayotis Verginis; Isabelle Vergne; Paul Verkade; Manish Verma; Patrik Verstreken; Tim Vervliet; Jörg Vervoorts; Alexandre T Vessoni; Victor M Victor; Michel Vidal; Chiara Vidoni; Otilia V Vieira; Richard D Vierstra; Sonia Viganó; Helena Vihinen; Vinoy Vijayan; Miquel Vila; Marçal Vilar; José M Villalba; Antonio Villalobo; Beatriz Villarejo-Zori; Francesc Villarroya; Joan Villarroya; Olivier Vincent; Cecile Vindis; Christophe Viret; Maria Teresa Viscomi; Dora Visnjic; Ilio Vitale; David J Vocadlo; Olga V Voitsekhovskaja; Cinzia Volonté; Mattia Volta; Marta Vomero; Clarissa Von Haefen; Marc A Vooijs; Wolfgang Voos; Ljubica Vucicevic; Richard Wade-Martins; Satoshi Waguri; Kenrick A Waite; Shuji Wakatsuki; David W Walker; Mark J Walker; Simon A Walker; Jochen Walter; Francisco G Wandosell; Bo Wang; Chao-Yung Wang; Chen Wang; Chenran Wang; Chenwei Wang; Cun-Yu Wang; Dong Wang; Fangyang Wang; Feng Wang; Fengming Wang; Guansong Wang; Han Wang; Hao Wang; Hexiang Wang; Hong-Gang Wang; Jianrong Wang; Jigang Wang; Jiou Wang; Jundong Wang; Kui Wang; Lianrong Wang; Liming Wang; Maggie Haitian Wang; Meiqing Wang; Nanbu Wang; Pengwei Wang; Peipei Wang; Ping Wang; Ping Wang; Qing Jun Wang; Qing Wang; Qing Kenneth Wang; Qiong A Wang; Wen-Tao Wang; Wuyang Wang; Xinnan Wang; Xuejun Wang; Yan Wang; Yanchang Wang; Yanzhuang Wang; Yen-Yun Wang; Yihua Wang; Yipeng Wang; Yu Wang; Yuqi Wang; Zhe Wang; Zhenyu Wang; Zhouguang Wang; Gary Warnes; Verena Warnsmann; Hirotaka Watada; Eizo Watanabe; Maxinne Watchon; Anna Wawrzyńska; Timothy E Weaver; Grzegorz Wegrzyn; Ann M Wehman; Huafeng Wei; Lei Wei; Taotao Wei; Yongjie Wei; Oliver H Weiergräber; Conrad C Weihl; Günther Weindl; Ralf Weiskirchen; Alan Wells; Runxia H Wen; Xin Wen; Antonia Werner; Beatrice Weykopf; Sally P Wheatley; J Lindsay Whitton; Alexander J Whitworth; Katarzyna Wiktorska; Manon E Wildenberg; Tom Wileman; Simon Wilkinson; Dieter Willbold; Brett Williams; Robin S B Williams; Roger L Williams; Peter R Williamson; Richard A Wilson; Beate Winner; Nathaniel J Winsor; Steven S Witkin; Harald Wodrich; Ute Woehlbier; Thomas Wollert; Esther Wong; Jack Ho Wong; Richard W Wong; Vincent Kam Wai Wong; W Wei-Lynn Wong; An-Guo Wu; Chengbiao Wu; Jian Wu; Junfang Wu; Kenneth K Wu; Min Wu; Shan-Ying Wu; Shengzhou Wu; Shu-Yan Wu; Shufang Wu; William K K Wu; Xiaohong Wu; Xiaoqing Wu; Yao-Wen Wu; Yihua Wu; Ramnik J Xavier; Hongguang Xia; Lixin Xia; Zhengyuan Xia; Ge Xiang; Jin Xiang; Mingliang Xiang; Wei Xiang; Bin Xiao; Guozhi Xiao; Hengyi Xiao; Hong-Tao Xiao; Jian Xiao; Lan Xiao; Shi Xiao; Yin Xiao; Baoming Xie; Chuan-Ming Xie; Min Xie; Yuxiang Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Congfeng Xu; En Xu; Haoxing Xu; Jing Xu; JinRong Xu; Liang Xu; Wen Wen Xu; Xiulong Xu; Yu Xue; Sokhna M S Yakhine-Diop; Masamitsu Yamaguchi; Osamu Yamaguchi; Ai Yamamoto; Shunhei Yamashina; Shengmin Yan; Shian-Jang Yan; Zhen Yan; Yasuo Yanagi; Chuanbin Yang; Dun-Sheng Yang; Huan Yang; Huang-Tian Yang; Hui Yang; Jin-Ming Yang; Jing Yang; Jingyu Yang; Ling Yang; Liu Yang; Ming Yang; Pei-Ming Yang; Qian Yang; Seungwon Yang; Shu Yang; Shun-Fa Yang; Wannian Yang; Wei Yuan Yang; Xiaoyong Yang; Xuesong Yang; Yi Yang; Ying Yang; Honghong Yao; Shenggen Yao; Xiaoqiang Yao; Yong-Gang Yao; Yong-Ming Yao; Takahiro Yasui; Meysam Yazdankhah; Paul M Yen; Cong Yi; Xiao-Ming Yin; Yanhai Yin; Zhangyuan Yin; Ziyi Yin; Meidan Ying; Zheng Ying; Calvin K Yip; Stephanie Pei Tung Yiu; Young H Yoo; Kiyotsugu Yoshida; Saori R Yoshii; Tamotsu Yoshimori; Bahman Yousefi; Boxuan Yu; Haiyang Yu; Jun Yu; Jun Yu; Li Yu; Ming-Lung Yu; Seong-Woon Yu; Victor C Yu; W Haung Yu; Zhengping Yu; Zhou Yu; Junying Yuan; Ling-Qing Yuan; Shilin Yuan; Shyng-Shiou F Yuan; Yanggang Yuan; Zengqiang Yuan; Jianbo Yue; Zhenyu Yue; Jeanho Yun; Raymond L Yung; David N Zacks; Gabriele Zaffagnini; Vanessa O Zambelli; Isabella Zanella; Qun S Zang; Sara Zanivan; Silvia Zappavigna; Pilar Zaragoza; Konstantinos S Zarbalis; Amir Zarebkohan; Amira Zarrouk; Scott O Zeitlin; Jialiu Zeng; Ju-Deng Zeng; Eva Žerovnik; Lixuan Zhan; Bin Zhang; Donna D Zhang; Hanlin Zhang; Hong Zhang; Hong Zhang; Honghe Zhang; Huafeng Zhang; Huaye Zhang; Hui Zhang; Hui-Ling Zhang; Jianbin Zhang; Jianhua Zhang; Jing-Pu Zhang; Kalin Y B Zhang; Leshuai W Zhang; Lin Zhang; Lisheng Zhang; Lu Zhang; Luoying Zhang; Menghuan Zhang; Peng Zhang; Sheng Zhang; Wei Zhang; Xiangnan Zhang; Xiao-Wei Zhang; Xiaolei Zhang; Xiaoyan Zhang; Xin Zhang; Xinxin Zhang; Xu Dong Zhang; Yang Zhang; Yanjin Zhang; Yi Zhang; Ying-Dong Zhang; Yingmei Zhang; Yuan-Yuan Zhang; Yuchen Zhang; Zhe Zhang; Zhengguang Zhang; Zhibing Zhang; Zhihai Zhang; Zhiyong Zhang; Zili Zhang; Haobin Zhao; Lei Zhao; Shuang Zhao; Tongbiao Zhao; Xiao-Fan Zhao; Ying Zhao; Yongchao Zhao; Yongliang Zhao; Yuting Zhao; Guoping Zheng; Kai Zheng; Ling Zheng; Shizhong Zheng; Xi-Long Zheng; Yi Zheng; Zu-Guo Zheng; Boris Zhivotovsky; Qing Zhong; Ao Zhou; Ben Zhou; Cefan Zhou; Gang Zhou; Hao Zhou; Hong Zhou; Hongbo Zhou; Jie Zhou; Jing Zhou; Jing Zhou; Jiyong Zhou; Kailiang Zhou; Rongjia Zhou; Xu-Jie Zhou; Yanshuang Zhou; Yinghong Zhou; Yubin Zhou; Zheng-Yu Zhou; Zhou Zhou; Binglin Zhu; Changlian Zhu; Guo-Qing Zhu; Haining Zhu; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Yanping Zhu; Yushan Zhu; Haixia Zhuang; Xiaohong Zhuang; Katarzyna Zientara-Rytter; Christine M Zimmermann; Elena Ziviani; Teresa Zoladek; Wei-Xing Zong; Dmitry B Zorov; Antonio Zorzano; Weiping Zou; Zhen Zou; Zhengzhi Zou; Steven Zuryn; Werner Zwerschke; Beate Brand-Saberi; X Charlie Dong; Chandra Shekar Kenchappa; Zuguo Li; Yong Lin; Shigeru Oshima; Yueguang Rong; Judith C Sluimer; Christina L Stallings; Chun-Kit Tong Journal: Autophagy Date: 2021-02-08 Impact factor: 13.391
Authors: Hana Van Campen; Jeanette V Bishop; Vikki M Abrahams; Helle Bielefeldt-Ohmann; Candace K Mathiason; Gerrit J Bouma; Quinton A Winger; Christie E Mayo; Richard A Bowen; Thomas R Hansen Journal: Viruses Date: 2020-09-08 Impact factor: 5.048